



HU000026267T2

(19) **HU****MAGYARORSZÁG**
Szellemi Tulajdon Nemzeti Hivatala(11) Lajstromszám: **E 026 267**(13) **T2****EURÓPAI SZABADALOM**
SZÖVEGÉNEK FORDÍTÁSA

(21) Magyar ügyszám: **E 11 738822** (51) Int. Cl.: **A61K 9/16** (2006.01)
(22) A bejelentés napja: **2011. 06. 30.** **A61K 9/28** (2006.01)
A61K 9/48 (2006.01)
A61K 9/50 (2006.01)
(96) Az európai bejelentés bejelentési száma: **EP 20110738822**
(97) Az európai bejelentés közzétételi adatai: **EP 2598122 A2** **2012. 02. 02.** (86) A nemzetközi (PCT) bejelentési szám: **PCT/IB 11/052896**
(97) Az európai szabadalom megadásának meghirdetési adatai: **EP 2598122 B1** **2015. 09. 16.** (87) A nemzetközi közzétételi szám: **WO 12014104**

(30) Elsőbbségi adatok: MI20101386 2010. 07. 27. IT 367720 P 2010. 07. 26. US	(73) Jogosult(ak): Gnosis S.p.A., 20121 Milano (IT)
(72) Feltaláló(k): GIOVANNONE, Daniele, I-03100 Frosinone (FR) (IT) DE ANGELIS, Carlo, I-03035 Fontana Liri (FR) (IT)	(74) Képviselő: Derzsi Katalin, SBGK Budapesti Nemzetközi Szabadalmi Iroda, Budapest

(54) **Sellakot és/vagy annak sóját és nátrium-keményítő-glikolátot tartalmazó kompozíció**

Az európai szabadalom ellen, megadásának az Európai Szabadalmi Közlönyben való meghirdetésétől számított kilenc hónapon belül, felszólalást lehet benyújtani az Európai Szabadalmi Hivatalnál. (Európai Szabadalmi Egyezmény 99. cikk(1))

A fordítást a szabadalmas az 1995. évi XXXIII. törvény 84/H. §-a szerint nyújtotta be. A fordítás tartalmi helyességét a Szellemi Tulajdon Nemzeti Hivatala nem vizsgálta.



(11) **EP 2 598 122 B1**

(12) **EUROPEAN PATENT SPECIFICATION**

(45) Date of publication and mention
of the grant of the patent:
16.09.2015 Bulletin 2015/38

(51) Int Cl.:
A61K 9/16 ^(2006.01) **A61K 9/48** ^(2006.01)
A61K 9/28 ^(2006.01) **A61K 9/50** ^(2006.01)

(21) Application number: **11738822.3**

(86) International application number:
PCT/IB2011/052896

(22) Date of filing: **30.06.2011**

(87) International publication number:
WO 2012/014104 (02.02.2012 Gazette 2012/05)

(54) **COMPOSITION COMPRISING SHELLAC AND/OR A SALT THEREOF AND SODIUM STARCH GLYCOLATE**

ZUSAMMENSETZUNG MIT SCHELLACK UND/ODER SALZ DARAUS UND
NATRIUMSTÄRKEGLYCOLAT

COMPOSITION COMPRENANT DE LA GOMME LAQUE ET/OU UN SEL CORRESPONDANT AINSI
QU'UN GLYCOLATE D'AMIDON SODIQUE

(84) Designated Contracting States:
**AL AT BE BG CH CY CZ DE DK EE ES FI FR GB
GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO
PL PT RO RS SE SI SK SM TR**

(30) Priority: **27.07.2010 IT MI20101386**
26.07.2010 US 367720 P

(43) Date of publication of application:
05.06.2013 Bulletin 2013/23

(73) Proprietor: **Gnosis S.p.A.**
20121 Milano (IT)

(72) Inventors:
• **GIOVANNONE, Daniele**
I-03100 Frosinone (FR) (IT)

• **DE ANGELIS, Carlo**
I-03035 Fontana Liri (FR) (IT)

(74) Representative: **Pistolessi, Roberto et al**
Dragotti & Associati Srl
Via Nino Bixio, 7
20129 Milano (IT)

(56) References cited:
WO-A1-01/76392 WO-A1-2009/064429
US-A1- 2004 103 821 US-A1- 2007 071 821

• **"Ardeysedon überzogene Tabletten, Omeprazol
Krewel 20mg/ -40mg, Valdoxan 25mg
Filmtabletten" In: "Rote Liste 2009", 1 January
2009 (2009-01-01), Rote Liste Service GmbH,
XP55022758, pages 1-4, paragraphs [49023],
[60226], [71250]**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

Description

[0001] The object of the present invention is a composition comprising shellac and/or a salt thereof and sodium starch glycolate and at least one physiologically acceptable excipient.

[0002] Said shellac and/or a salt thereof according to the present invention can be aqueous or alcoholic, preferably aqueous.

[0003] Said shellac salt according to the present invention can be a potassium salt, an ammonium salt or a salt of a basic amino acid and/or a mixture thereof, wherein said basic amino acid is preferably selected from among arginine, lysine, ornithine and/or a mixture thereof.

[0004] The composition according to the present invention is preferably a coating composition for solid oral formulations, more preferably tablets (acidic, neutral, basic, according to the nature of the active ingredient and/or nutraceutical, dietetic or food supplement contained in them), capsules, pellets, granulates and/or microgranulates.

[0005] Said coating composition according to the present invention is preferably a gastroresistant coating composition.

[0006] According to a preferred embodiment of the present invention, said composition can constitute a system ready for use for pharmaceutical, dietetic, nutraceutical or food coatings.

STATE OF THE ART

[0007] It is known that in many cases it is necessary for pharmaceutical, dietetic, nutraceutical or food solid oral formulations to be able to pass through the stomach intact, in order to release their content in the gastrointestinal tract. This is the case, for example, when the active ingredient and/or the nutraceutical, dietetic or food supplement is made inactive by the gastric juice or irritates the gastric wall; in order to make the active ingredient and/or nutraceutical, dietetic or food supplement reach the intestine in a concentration such as to be able to act locally or to obtain greater absorption of the active ingredient and/or of the nutraceutical, dietetic or food supplement through a limitation of the area in which it is released.

[0008] This purpose can be obtained by coating the pharmaceutical, dietetic, nutraceutical or food solid oral formulations with a gastroresistant (enteric) coating.

[0009] Enteric coatings commonly consist of materials with characteristics of: pH-dependent solubility, between pH 5 and 7; quick dissolving in a non-gastric medium; insensitivity to variations in ionic force; stability in storage.

[0010] In the pharmaceutical industry enteric coatings are widely used, with a vast choice of enteric materials like hydroxypropyl methylcellulose phthalate (HPMCP), polymers or copolymers of acrylic or methacrylic acid (for example Eudragit™), cellulose acetate phthalate (CAP) and polyvinyl acetate phthalate (PVAP). All of these enteric materials were developed to provide a vast range of coatings that are soluble in organic solvents or in aqueous dispersions.

[0011] However, the approval for use of these materials in the pharmaceuticals industry has required numerous application studies and rigorous testing, using an amount of resources that is unfeasible in the food sector. Consequently, these enteric materials are not approved for food use and cannot be used legally as enteric coatings for non-pharmaceutical solid oral formulations, including nutraceutical or dietetic supplements. There are very few materials that can be used as enteric coating in the nutraceutical, dietetic or food field.

[0012] One example is Zein, a prolamine obtained from corn used in the past as a coating material, but which has very poor enteric properties as well as numerous problems connected to the coating techniques, to costs and to environmental impact.

[0013] Another example of a material that can be used as an enteric coating in the nutraceutical, dietetic or food field is shellac.

[0014] Shellac is a natural substance, acidic in nature, recognised as GRAS or "Generally Recognized As Safe" by the American Food and Drug Administration (FDA). This makes it suitable for use as a coating for drugs, nutraceuticals or dietetics in solid oral formulations, as well as for food products.

[0015] Shellac is the purified product of lac, a natural resinous oligomer with molecular weight of about 1000 D, secreted by the parasitic insect *Kerria lacca*. It is made up of polyesters, mainly aleuritic acid, shellolic acid, and a small amount of aliphatic acids, with variable composition according to the species of insects as well as the tree hosting them from which the raw material is objected. It is also a known filming agent, thanks to its excellent filmogenous properties, its shininess and its low permeability to gas and water vapour.

[0016] Although it has these advantages, the use of shellac as pharmaceutical, nutraceutical, dietetic or food excipient is low with respect to that of synthetic or partially synthetic polymers (for example polymethacrylates and cellulose derivatives).

[0017] This is due mainly to problems of instability linked to shellac, which over time tends to degenerate, modifying its physical-chemical properties and gradually losing or increasing the properties of gastroresistance.

[0018] Conventional films of shellac, prepared in alcohol solutions, indeed display a progressive and pronounced hardening, induced by a continuous polymerisation process. This translates, as well as into the partial separation of the

coating film from the core containing an active ingredient and/or a nutraceutical, dietetic or food supplement, into a loss of gastric resistance and into a decreased solubility at the level of the intestinal fluids, which can cause great changes in the dissolving profiles of the active ingredient and/or of the nutraceutical, dietetic or food supplement. Indeed, considering the poor solubility in water of shellac and its dissolving at a relatively high pH (about 7.3), a further reduction of solubility in the intestinal fluids can cause an incomplete release of the active ingredient and/or of the nutraceutical, dietetic or food supplement by the pharmaceutical and/or nutraceutical, dietetic or food form.

[0019] Moreover, the increased permeability to gastric fluid caused by the loss of gastric resistance of the film of shellac can cause the degradation of acid-labile active ingredients and/or nutraceutical, dietetic or food supplements.

[0020] In order to overcome such limitations, alternative formulations in aqueous solution have been proposed in which shellac is combined with hydroxides of alkaline metals, in particular sodium or ammonium hydroxide.

[0021] Although these films in aqueous solution display better stability with respect to conventional films in alcohol solution, the drawbacks due to ageing still remain strongly linked both to the quality of the shellac used (origin, refining process) and to the chemical-physical characteristics of the cores to be coated.

[0022] Numerous technologies and formulations have been studied as possible solutions to the problems connected to shellac-based coating agents, but even through the combination of these different techniques it has not yet been possible to solve the existing problems without producing new ones.

[0023] US20070071821 describes the association between a shellac salt and an alginate for the formulation of a coating with improved enteric properties, entirely made up of materials approved for food use. This combination, whilst being advantageous in terms of functionality with respect to other shellac salts in aqueous solution, does not yet effectively overcome the limitations of shellac-based coatings linked to ageing of the product.

[0024] The patent application WO 2009/064429 shows a shellac comprising a disintegrant such as sodium alginate. The family of patents referring to US20040103821 describes a shellac coating agent in aqueous solution, comprising a basic amino acid and/or a basic phosphate. Also in this case, however, the shellac films obtained are relatively insensitive to pH and disintegrate in two or three hours, irrespective of the acidity or alkalinity of the solution, instead behaving like erodible films that dissolve as a function of the time. In particular, it displayed limitations linked both to the stability and to the functionality of the coating in relation to the chemical-physical characteristics of the material coated.

[0025] There is therefore a need to provide a composition accepted in the field of pharmaceuticals, as well as of nutraceuticals, dietetics or foods that has improved ability to control release and improved stability over time.

DESCRIPTION

[0026] It has now been surprisingly found that a composition containing shellac in combination with sodium starch glycolate, as defined by claim 1, overcomes the limitations of the state of the art and has optimal properties in terms of appearance, hardness, adhesion and stability.

[0027] The term "shellac", according to the present invention, refers to a natural polymer equipped with thermoplastic properties, also known under the name E 904.

[0028] Sodium starch glycolate is a sodium salt obtained from potato starch, approved by the Food and Drug Administration (FDA) as a disintegrant used both in pharmaceutical and food products. Therefore it is an excipient present both in the GRAS list in the USA and in the list of products that can be used as a food additive in Europe.

[0029] It is known in literature that the source of starch, the size of the particles, the viscosity, the degree of substitution and of cross-linking have an influence on the functionality of sodium starch glycolate.

[0030] Its main function is to be a superdisintegrant of solid oral formulations, preferably tablets.

[0031] The term "superdisintegrant" according to the present invention refers to a disintegrant of the second generation, characterised by particularly effective activity.

[0032] The action mechanism with which it operates is drawing water inside the solid pharmaceutical, nutraceutical, dietetic or food form causing the subsequent swelling and development of a disintegration force inside the aforementioned form.

[0033] The lowering of the pH of the solution in which it is dissolved, or dispersed, to very acidic values reduces the speed and degree of absorption of the liquid by the sodium starch glycolate and consequently its disintegrant power.

[0034] Figure 1 shows the difference in disintegrant power as a function of the pH of some of the most well-known superdisintegrants. From the analysis of Figure 1 it is clear that sodium starch glycolate is the only one of the selected disintegrants having a low disintegrant power at acidic pH. On the other hand, it displays a high disintegrant power at pH neutral.

[0035] It has now been surprisingly found that, when shellac and/or a salt thereof is added to it, sodium starch glycolate forms a composition resistant to acids (for example in an environment with pH between 1 and 5) capable of easily disintegrating as soon as the conditions become slightly alkaline (for example in an environment with pH between 6 and 7), thus performing the functions of an excellent enteric excipient.

[0036] The presence of sodium starch glycolate also makes it possible to stabilise the shellac and/or salt thereof over

time thanks to the fact that it minimises its polymerisation and hardening. In this way, the chemical-physical characteristics of the shellac and/or of a salt thereof remain stable over time ensuring a more homogeneous profile of the release characteristics of the active ingredient and/or nutraceutical, dietetic or food supplement. No other known disintegrant for food, nutraceutical, dietetic or food use allows the same advantages to be obtained.

[0037] The object of the present invention is thus a composition comprising shellac and/or a salt thereof and sodium starch glycolate and at least one physiologically acceptable excipient.

[0038] The shellac and/or a salt thereof according to the present invention can be aqueous or alcoholic, preferably aqueous.

[0039] The shellac salt according to the present invention is preferably selected from among a potassium salt, an ammonium salt or a salt of a basic amino acid and/or a mixture thereof, where said basic amino acid is preferably selected from among arginine, lysine, ornithine and/or a mixture thereof.

[0040] The most preferred basic amino acid according to the invention is arginine.

[0041] The composition according to the present invention is preferably a coating composition for solid oral formulations, more preferably a gastroresistant coating composition (film). Solid oral formulations according to the invention preferably refer to tablets (acidic, neutral, basic), capsules, pellets, granulates and/or microgranulates.

[0042] Said composition displays a functionality highly sensitive to pH, irrespective of the chemical-physical characteristics of the material coated and it ensures homogeneity of gastroresistance over time.

[0043] The composition containing shellac and/or a salt thereof and sodium starch glycolate of the invention disintegrates little in an acidic environment and easily at neutral/alkaline pH.

[0044] According to a preferred embodiment of the present invention, said composition can constitute a system ready for use for pharmaceutical, nutraceutical, dietetic or food coatings.

[0045] A "system ready for use" according to the present invention refers to a mixture that is either liquid (for example a solution) or semi-solid (for example a suspension or dispersion) that can be applied directly on the solid oral form to be coated, without the need to reformulate the final mixture.

[0046] Sodium starch glycolate is commercially available as type A and type B, which differ in their different sodium content. Indeed, type A contains from 2.8 to 4.2% by weight of sodium with respect to the total weight, whereas type B contains from 2.0 to 3.4% by weight of sodium with respect to the total weight. The pH of an aqueous dispersion containing 3.3% sodium starch glycolate by weight varies from 3 to 5 or from 5.5 to 7.5 according to the type used.

[0047] In the composition according to the present invention both sodium starch glycolate of type A and of type B and/or a mixture of them can be used.

[0048] In the composition according to the present invention the sodium starch glycolate is preferably used in the form of powder with granulometry of between 0.5 and 200 micron, more preferably between 10 and 50 micron.

[0049] In the compositions according to the present invention, the shellac and/or a salt thereof is preferably contained in an amount between 1 and 99% by weight with respect to the total weight, more preferably between 50 and 95% by weight with respect to the total weight.

[0050] In the compositions according to the present invention, the sodium starch glycolate is preferably contained in an amount between 0.05 and 70% by weight with respect to the total weight, more preferably between 0.1% and 50% by weight with respect to the total weight.

[0051] According to a preferred embodiment of the invention, the shellac and/or a salt thereof and the sodium starch glycolate are present in equal amounts.

[0052] The composition according to the present invention is preferably formulated in the forms of a solution and/or suspension and/or powder to be reconstituted in water, more preferably in the form of an aqueous suspension.

[0053] The composition according to the present invention can also be formulated in the form of a solution and/or suspension and/or powder to be reconstituted in water, preferably in the form of a spray suspension.

[0054] The composition according to the present invention can contain one or more further physiologically acceptable excipients, preferably plasticizers, suspension agents or glidants and/or dilutants.

[0055] Plasticizers according to the invention are preferably selected from among triethyl citrate, polyethylene glycol, polypropylene glycol, glycerol monostearate, polyols, glycerine, vegetable oils and/or a mixture thereof.

[0056] Said plasticizers are preferably added in an amount between 2 and 50% by weight with respect to the total weight, preferably to optimise the flexibility of the composition. Suspension agents or glidants according to the invention are preferably selected from among silica, precipitated silica, talc and/or a mixture thereof.

[0057] Dilutants according to the invention are preferably selected from among talc, titanium dioxide and/or a mixture thereof.

[0058] A further object of the present invention is a process for preparing the composition as described above that comprises the steps of:

- a) preparing the solution of shellac and/or a salt thereof, solution A;
- b) preparing the aqueous suspension of sodium starch glycolate, suspension B;

c) mixing solution A and suspension B.

[0059] In the preparation of solution A it is possible to use all types of shellac known on the market.

[0060] According to the invention, in step a) the shellac and/or a salt thereof is dissolved in a polar solvent, preferably a C₁-C₄ alcohol, more preferably methanol, ethanol, isopropanol, n-propanol, and the like, or water and/or in a mixture thereof, even more preferably it is dissolved in water.

[0061] In a more preferred embodiment of the present invention the shellac is dissolved in water in the form of ammonium, potassium or basic amino acid salt.

[0062] Preferably, said step a) according to the invention is carried out under stirring and/or heat.

[0063] The term "heat" according to the present invention, refers to a temperature between room temperature and the boiling temperature of the solvent used.

[0064] According to the invention, in step c) the shellac and/or a salt thereof is added to the aqueous suspension of sodium starch glycolate, suspension B, to give a composition that, applied on any type of solid oral formulation, preferably tablets (acidic, neutral, basic), capsules, pellets, granulates and/or microgranulates, forms a coating that disintegrates in slightly alkaline conditions (for example in an environment with pH between 6 and 7).

[0065] In a preferred embodiment of the present invention, the shellac is heated in water, under stirring, to a temperature of between 50 and 100°C, preferably between 70 and 75°C. Then the amino acid and the aqueous suspension of sodium starch glycolate, obtained by dispersing the sodium starch glycolate in water, are added. Again under stirring, the temperature is brought to about 80°C and it is stirred again for about 30 minutes. The solution thus obtained is then cooled.

[0066] In a further preferred embodiment of the present invention said process is carried out at a temperature of between 50 and 100°C, preferably between 50 and 80°C.

[0067] The pH of the mixture, or one of the components inside the mixture, can be adjusted and/or selected to make said solution or suspension more manageable.

[0068] The solution of shellac and/or of a salt thereof and sodium starch glycolate can, after possible mixing with one or more further excipients according to the present invention, be applied onto solid oral formulations through the methods of the prior art.

[0069] Preferred forms of application according to the present invention are film-coating in coating pans and/or film-coating of the pellets and/or enteric microencapsulation on a fluid bed and/or spraying.

[0070] A further object of the present invention is the use of the composition containing shellac and/or a salt thereof and sodium starch glycolate as described above for coating pharmaceutical, nutraceutical, dietetic or food solid oral formulations.

[0071] The term "capsule" according to the present invention is intended to include rigid capsules, soft capsules, pastilles, lozenges and/or pills.

[0072] A further object of the present invention is a solid oral formulation coated with the composition comprising shellac and/or a salt thereof and sodium starch glycolate as described above. Preferably, the solid oral formulation coated according to the invention is a gastroresistant formulation in which said gastroresistance is given by the coating composition containing shellac and/or a salt thereof and sodium starch glycolate mentioned above (film).

[0073] Solid oral formulation according to the invention preferably refer to tablets (acidic, neutral, basic), capsules, pellets, granulates and/or microgranulates.

[0074] The coated pharmaceutical, nutraceutical, dietetic or food solid oral formulation according to the invention has the advantage of being stable over time and it ensures a homogeneous release of the active ingredient and/or of the nutraceutical, dietetic or food supplement.

[0075] Therefore, the presence of the composition containing shellac and/or a salt thereof and sodium starch glycolate leads to improved stability, improved characteristics of release and disintegration of the solid oral formulation coated by it.

[0076] The coated composition of the invention can contain one or more active ingredients and/or nutraceutical, dietetic or food supplements and at least one physiologically acceptable adjuvant.

[0077] Examples of active ingredients and/or nutraceutical or dietetic supplements that can be coated with the composition of the present invention are for example SAME (S-adenosyl methionine) and/or its physiologically acceptable salts, lansoprazole, pantoprazole, ibuprofen, lactic ferments, NADH or NAD (nicotinamide adenine dinucleotide), SOD (superoxide dismutase), nattokinase, preferably SAME and/or its physiologically acceptable salts.

[0078] According to a preferred embodiment the coated composition of the invention comprises a core containing at least one active ingredient and/or nutraceutical, dietetic or food supplement and at least one physiologically acceptable adjuvant, surrounded externally by the composition containing shellac and/or a salt thereof and sodium starch glycolate as described above.

[0079] Said physiologically acceptable adjuvant is preferably selected from among dilutants, binders, disintegrants, stabilizers, glidants or lubricants.

[0080] Said dilutants include, for example, lactose, starches, microcrystalline cellulose, calcium phosphate and calcium carbonate.

EP 2 598 122 B1

[0081] Said binders include, for example, PVP (polyvinyl pyrrolidone), gelatine, cellulose derivatives (for example HPMC, CMC, MC), tragacanth, gum arabic and polyethylene glycols.

[0082] Said disintegrants include, for example, corn starch, cellulose (for example, microcrystalline cellulose, carboxymethyl cellulose (CMC), croscarmellose), alginates and polyvinyl pyrrolidones (for example crospovidone).

[0083] Said stabilizers include, for example, calcium or magnesium oxide, calcium or magnesium hydroxide, calcium or magnesium chloride.

[0084] Said glidants include, for example, talc, colloidal silica and precipitated silica.

[0085] Said lubricants include, for example, stearates, stearic acid, talc, wax and other fatty substances.

[0086] From the experimental data of the Examples given hereafter, it can be seen that the disintegration times of the formulations according to the present invention at pH 6.8 are within specifications according to the disintegration test described in the USP current edition and that the variation of the disintegration at pH 6.8 is constant over time after the samples are conserved at 40 °C for 6 months.

[0087] The following examples are intended to better explain the present invention.

EXAMPLES

Stability tests of the gastroresistant film on the end product

[0088] The stabilities at 40°C and 75% relative humidity (R.H.) (STRESS TEST) and at room temperature in the long term (SHELF LIFE) of the compositions of the Examples were evaluated through the variations of the disintegration time of the gastroresistant coating object of the present invention both at pH 1.2 and at pH 6.8 according to what is described in United States Pharmacopeia USP, current edition.

[0089] Moreover, the water content (K.F.), the active ingredient content and the total impurity content were determined to check that the tablets did not undergo particular variations such as to jeopardise the gastroresistance test.

Stress test

[0090] The tablets were packaged in capped and sealed glass flasks so as to reproduce the final packaging conditions for products containing these active ingredients (in general, aluminium/aluminium blister pack).

[0091] The samples thus prepared were conserved for six months in thermostated oven at a temperature of $40 \pm 2^\circ\text{C}$ and 75% R.H.

[0092] Samples coming from different batches were used for the tablets of the Examples where each sample, for each batch, was sampled after 0, 1, 3 and 6 months.

Shelf life

[0093] The tablets were packaged in capped and sealed glass flasks so as to reproduce the final packaging conditions (in general, aluminium/aluminium blister pack).

[0094] The samples were selected according to the same ways and amounts described for the stress test and conserved in a thermostated environment at a temperature of $25 \pm 2^\circ\text{C}$ and humidity equal to 60% R.H.

[0095] Samples coming from one batch were used for the Examples, where each sample was sampled after 0, 3, 6, 12 months.

[0096] All of the examples refer to the preparation of a standard laboratory batch of 2.00 kg of tablets.

EXAMPLE 1: 30 mg gastroresistant Lansoprazole tablets

[0097]

A. Lansoprazole	30,00 mg
B Microcrystalline cellulose.	70,00 mg
C. Mannitol	80,00 mg
D. Sorbitol	50,00 mg
E. PVP CL	20,00 mg
F. Silicon dioxide	2,00 mg
G. Stearic acid	10,00 mg
H. Magnesium stearate	2,00 mg

EP 2 598 122 B1

(continued)

Total core weight	264,00 mg
I. Arginine Shellac	30,00 mg
L. Sodium starch glycolate	6,0 mg
M. Titanium dioxide	5,00 mg
N. Talc	10,00 mg
O. Triethyl citrate	5,00 mg
P. Precipitated silica	2,00 mg
Q. Curcumin	0,050 mg
Total tablet weight	322,05 mg

1. Mixing

[0098] The working environment is conditioned at a temperature of 25 °C and at a relative humidity value equal to about 40% R.H. Then A, B, C, D, E, F, G and H are transferred in the amounts indicated above, into the mixer, leaving them under stirring for about 30 minutes. At the end of such an operation, the resulting mixture is transferred into dry recipients, still controlling humidity and temperature.

2. Compression

[0099] The final compression of the mixture is carried out through a rotary machine equipped with punches of suitable shape and size for the weight of the core, producing tablets with a hardness of at least 20 KP. The tablets produced have a hardness of between 20 and 25 Kp.

[0100] Friability: ≤ 1,0%; disintegration time: ≤ 15 minutes (measured according to the method described in U.S.P. Current edition).

3. Film-coating of the tablet

[0101] In a suitably sized recipient the shellac is dissolved with the arginine base at 60°C, the sodium starch glycolate is added and it is brought to 80°C until a solution at 20 % p/v of the arginine shellac salt with 4% sodium starch glycolate in suspension. Thereafter, under constant stirring, the triethyl citrate is slowly added.

[0102] In another steel recipient again equipped with a stirrer, the talc, the titanium dioxide, the precipitated silica and the curcumin are dispersed in 4.0 l of deionized water. The resulting suspension is poured into the arginine shellac solution, washing the recipient with about 1.0l of deionized water, then diluting with another 4.0l of deionized water. The enteric coating is carried out at a temperature of the cores of 45°C and, once the gastroresistant coating is complete, it is left to dry for another 10 minutes still at 45°C. Finally, it is necessary to wait until the temperature lowers to 32-33°C so as to be able to start emptying the coating pan, taking care to keep the tablets in suitable bags that are impermeable to humidity. All of the tests foreseen by the quality specifications are carried out on them.

Table 1

Stress test of Batches 001 and 014 - 30 mg lansoprazole tablets (quali/quantitative composition from Example 1)					
Batch (T/t) ¹	Humidity % (K.F.)	Total impurities	Count mg/cpr	Resistance to gastric juice at pH 1,2 ² (minutes)	Disintegration time at pH 6,8 ² (minutes)
001 (20/0)	0,55	0,12	30,4	60,00	27,00
001A (40/1)	0,45	0,18	30,2	60,00	28,00
001B (40/3)	0,65	0,16	30,0	60,00	30,00
001C (40/6)	0,44	0,19	30,1	60,00	29,00

EP 2 598 122 B1

(continued)

Stress test of Batches 001 and 014 - 30 mg lansoprazole tablets (quali/quantitative composition from Example 1)					
Batch (T/t) ¹	Humidity % (K.F.)	Total impurities	Count mg/cpr	Resistance to gastric juice at pH 1,2 ² (minutes)	Disintegration time at pH 6,8 ² (minutes)
014 (20/0)	0,48	0,23	29,9	60,00	25,00
014A (40/1)	0,43	0,22	30,1	60,00	26,00
014B (40/3)	0,56	0,32	29,8	60,00	27,00
014C (40/6)	0,51	0,28	29,7	60,00	28,00
¹ Temperature (°C)/time (months); ² Disintegration test according to USP current edition.					

[0103] The data in Table 1 shows that in the presence of sodium starch glycolate, the disintegration times at pH 6.8 are within specifications according to the disintegration test described in USP current edition and the variation of the disintegration again at pH 6.8 is constant over time after the samples are conserved at 40 °C for 6 months.

Table 2

Shelf life of Batch 027- 30 mg lansoprazole tablets (quali/quantitative composition of Example 1)					
Batch (T/t) ¹	Humidity % (K.F.)	Total impurities	Count mg/cpr	Resistance to gastric juice at pH 1,2 ² (minutes)	Disintegration time at pH 6,8 ² (minutes)
027 (20/0)	0,33	0,25	30,23	60,00	27,00
027A (25/3)	0,35	0,33	31,21	60,00	27,00
027B (25/6)	0,44	0,38	29,83	60,00	29,00
027C (25/12)	0,54	0,31	29,79	60,00	31,00
¹ Temperature (°C)/time (months); ² Disintegration test according to USP current edition.					

EXAMPLE 2: 30 mg gastroresistant Lansoprazole tablets without sodium starch glycolate

[0104]

A. Lansoprazole	30,00 mg
B Microcrystalline cellulose	70,00 mg
C. Mannitol	80,00 mg
D. Sorbitol	50,00 mg
E. PVP CL	20,00 mg
F. Silicon dioxide	2,00 mg
G. Stearic acid	10,00 mg
E. Magnesium stearate	2,00 mg
Total core weight	264,00 mg
F. Arginine Shellac	30,00 mg
G. Titanium dioxide	5,00 mg
H. Talc	10,00 mg
I. Triethy citrate	5,00 mg
L. Precipitated silica	2,00 mg

EP 2 598 122 B1

(continued)

M. Curcumin	0,050 mg
Total tablet weight	316,05 mg

Table 3

Stress test of Batches 002 and 015- 30 mg lansoprazole tablets (quali/quantitative composition of Example 2)					
Batch (T/t) ¹	Humidity % (K.F.)	Total impurities	Count mg/cpr	Resistance to gastric juice at pH 1,2 ² (minutes)	Disintegration time at pH 6,8 ² (minutes)
002 (20/0)	0,59	0,23	30,32	60,00	44,00
002A (40/1)	0,55	0,18	30,64	60,00	53,00
002B (40/3)	0,61	0,26	30,15	60,00	63,00
002C (40/6)	0,74	0,27	29,71	60,00	69,00
015 (20/0)	0,66	0,28	30,56	60,00	47,00
015A (40/1)	0,61	0,23	30,99	60,00	58,00
015B (40/3)	0,67	0,29	30,43	60,00	65,00
015C (40/6)	0,73	0,37	30,03	60,00	79,00
¹ Temperature (°C)/time (months); ² Disintegration test according to USP current edition.					

[0105] The data in Table 2 shows that in the absence of sodium starch glycolate, the disintegration times at pH 6.8 (according to USP current edition) are considerably longer at time zero, and the variation thereof again at pH 6.8 is not constant over time after the samples are conserved at 40 °C for 6 months.

Table 4

Shelf life of Batch 028- 30 mg lansoprazole tablets without sodium starch glycolate (quali/quantitative composition of Example 2)					
Batch (T/t) ¹	Humidity % (K.F.)	Total impurities	Count mg/cpr	Resistance to gastric juice at pH 1,2 ² (minutes)	Disintegration time at pH 6,8 ² (minutes)
028 (20/0)	0,54	0,38	31,34	60,0	46,00
028A (25/3)	0,51	0,29	31,23	60,0	50,00
028B (25/6)	0,56	0,34	30,21	60,0	55,00
028C (25/12)	0,69	0,39	29,67	60,0	69,00
¹ Temperature (°C)/time (months); ² Disintegration test according to USP current edition.					

EXAMPLE 3: 40.0 mg gastroresistant sodium pantoprazole tablets

[0106]

EP 2 598 122 B1

A. Sodium pantoprazole	40,00 mg
C. Maltodextrine	70,00 mg
D. Mannitol	50,00 mg
E. Calcium sulphate dihydrate	40,00 mg
F. Calcium phosphate dihydrate	40,00 mg
G. Magnesium stearate	20,00 mg
H. Dried malic acid	80,00 mg
I. Stearic acid	40,00 mg
Total core weight	380,00 mg
L. Arginine Shellac	30,00 mg
M. Sodium starch glycolate	6,0 mg
N. Titanium dioxide	5,00 mg
O. Talc	10,00 mg
P. Triethyl citrate	5,00 mg
Q. Precipitated silica	2,00 mg
R. Yellow tartrazine	0,050 mg
Total tablet weight	438,05 mg

[0107] The tablets were prepared according to the ways described in Example 1 using the components and the amounts indicated above.

[0108] The cores, due to the presence of malic acid, are characterised by having an acidic pH to test the behaviour of the film for this kind of type.

Table 5

Stress test of Batches 003 and 016- 40 mg sodium pantoprazole tablets (quali/quantitative composition of Example 3)					
Batch (T/t) ¹	Humidity % (K.F.)	Total impurities	Count mg/cpr	Resistance to gastric juice at pH 1,2 ² (minutes)	Disintegration time at pH 6,8 ² (minutes)
003 (20/0)	0,67	0,42	41,53	60,00	25,00
003A (40/1)	0,85	0,38	41,25	60,00	26,00
003B (40/3)	0,65	0,46	40,04	60,00	31,00
003C (40/6)	0,84	0,59	40,11	60,00	28,00
016 (20/0)	0,76	0,51	40,59	60,00	26,00
016A (40/1)	0,88	0,45	41,02	60,00	28,00
016B (40/3)	0,79	0,48	40,34	60,00	32,00
016C (40/6)	0,83	0,62	40,22	60,00	30,00
¹ Temperature (°C)/time (months); ² Disintegration test according to USP current edition.					

[0109] The data in Table 5 shows that, for the tablets with film-coated acidic cores with the presence of sodium starch glycolate in the film, the disintegration times at pH 6.8 are within specifications according to the disintegration test described in USP current edition and the variation of the disintegration again at pH 6.8 is constant over time after the samples are conserved at 40 °C for 6 months.

EP 2 598 122 B1

Table 6

Shelf life of Batch 029- 40 mg sodium pantoprazole tablets (quali/quantitative composition of Example 3)					
Batch (T/t) ¹	Humidity % (K.F.)	Total impurities	Count mg/cpr	Resistance to gastric juice at pH 1,2 ² (minutes)	Disintegration time at pH 6,8 ² (minutes)
029 (20/0)	0,45	0,65	40,00	60,00	24,00
029A (25/3)	0,67	0,44	40,42	60,00	25,00
029B (25/6)	0,72	0,58	39,94	60,00	28,00
029C (25/12)	0,88	0,68	39,72	60,00	28,00
¹ Temperature (°C)/time (months); ² Disintegration test according to USP current edition.					

EXAMPLE 4: 40.0 mg gastroresistant sodium pantoprazole tablets without sodium starch glycolate

[0110]

A. Sodium pantoprazole	40,00 mg
C. Maltodextrine	70,00 mg
D. Mannitol	50,00 mg
E. Calcium sulphate dihydrate	40,00 mg
F. Calcium phosphate dihydrate	40,00 mg
G. Magnesium stearate	20,00 mg
H. Malic acid	80,00 mg
I. Stearic acid	40,00 mg
Total core weight	380,00 mg
L. Arginine Shellac	30,00 mg
M. Titanium dioxide	5,00 mg
N. Talc	10,00 mg
O. Triethyl citrate	5,00 mg
P. Precipitated silica	2,00 mg
Q. Yellow tartrazine	0,050 mg
Total tablet weight	432,05 mg

Table 7

Stress test of Batches 004 and 017- 40 mg sodium pantoprazole tablets without disintegrant (quali/quantitative composition of Example 4)					
Batch (T/t) ¹	Humidity % (K.F.)	Total impurities	Count mg/cpr	Resistance to gastric juice at pH 1,2 ² (minutes)	Disintegration time at pH 6,8 ² (minutes)
004 (20/0)	0,44	0,54	40,63	60,00	45,00
004A (40/1)	0,65	0,32	39,35	60,00	56,00
004B (40/3)	0,59	0,56	41,04	60,00	65,00
004C (40/6)	0,76	0,63	39,71	60,00	68,00

EP 2 598 122 B1

(continued)

Stress test of Batches 004 and 017- 40 mg sodium pantoprazole tablets without disintegrant (quali/quantitative composition of Example 4)					
Batch (T/t) ¹	Humidity % (K.F.)	Total impurities	Count mg/cpr	Resistance to gastric juice at pH 1,2 ² (minutes)	Disintegration time at pH 6,8 ² (minutes)
017 (20/0)	0,39	0,65	41,33	60,00	50,00
017A (40/1)	0,58	0,55	40,00	60,00	62,00
017B (40/3)	0,53	0,62	40,24	60,00	68,00
017C (40/6)	0,64	0,68	39,00	60,00	76,00
¹ Temperature (°C)/time (months); ² Disintegration test according to USP current edition.					

[0111] The data in Table 7 shows that, for tablets with acidic film-coated cores without the presence of sodium starch glycolate in the coating film, they have considerably longer disintegration times at pH 6.8 (according to USP current edition) at time zero, and the variation thereof again at pH 6.8 is not constant over time after the samples have been conserved at 40 °C for 6 months.

Table 8

Shelf life of Batch 030- 40 mg sodium pantoprazole tablets (quali/quantitative composition of Example 4)					
Batch (T/t) ¹	Humidity % (K.F.)	Total impurities	Count mg/cpr	Resistance to gastric juice at pH 1,2 ² (minutes)	Disintegration time at pH 6,8 ² (minutes)
030 (20/0)	0,46	0,52	41,09	60,00	52,00
030A (25/3)	0,44	0,44	40,75	60,00	57,00
030B (25/6)	0,65	0,61	40,74	60,00	58,00
030C (25/12)	0,69	0,63	39,69	60,00	69,00
¹ Temperature (°C)/time (months); ² Disintegration test according to USP current edition.					

EXAMPLE 5: 40,0 mg gastroresistant sodium pantoprazole tablets with crospovidone (Kollidon CL)

[0112]

A. Sodium pantoprazole	40,00 mg
C. Maltodextrine	70,00 mg
D. Mannitol	50,00 mg
E. Calcium sulphate dehydrate	40,00 mg
F. Calcium phosphate dihydrate	40,00 mg
G. Magnesium stearate	20,00 mg
H. Malic acid	80,00 mg
I. Stearic acid	40,00 mg
Total core weight	380,00 mg
L. Arginine Shellac	30,00 mg
M. Crospovidone (Kollidon CL)	6,0 mg
N. Titanium dioxide	5,00 mg
O. Talc	10,00 mg

EP 2 598 122 B1

(continued)

P. Triethyl citrate	5,00 mg
Q. Precipitated silica	2,00 mg
R. Yellow tartrazine	0,050 mg
Total tablet weight	438,05 mg

Table 9

Stress test of Batches 005 and 018- 40 mg sodium pantoprazole tablets with Crospovidone as disintegrant (quali/quantitative composition of Example 5)					
Batch (T/t) ¹	Humidity % (K.F.)	Total impurities	Count mg/cpr	Resistance to gastric juice at pH 1,2 ² (minutes)	Disintegration time at pH 6,8 ² (minutes)
005 (20/0)	0,65	0,49	41,54	34,00	-----
005A (40/1)	0,55	0,37	40,76	45,00	-----
005B (40/3)	0,53	0,46	40,14	37,00	-----
005C (40/6)	0,69	0,58	40,51	29,00	-----
018 (20/0)	0,58	0,52	40,43	42,00	-----
018A (40/1)	0,53	0,67	40,78	55,00	-----
018B (40/3)	0,69	0,61	39,98	47,00	-----
018C (40/6)	0,71	0,64	40,11	49,00	-----
¹ Temperature (°C)/time (months); ² Disintegration test according to USP current edition.					

[0113] The data in Table 9 shows that the acidic film-coated tablets in the presence of Crospovidone (Kollidon CL) in the coating film replacing the sodium starch glycolate as another superdisintegrant, do not pass the acid resistance test of at least one hour in an acidic environment at pH 1.2 according to USP current edition. Indeed, the disintegration test at pH 6.8 is cancelled.

Table 10

Shelf life of Batch 031- 40 mg sodium pantoprazole tablets (quali/quantitative composition of Example 5)					
Batch (T/t) ¹	Humidity % (K.F.)	Total impurities	Count mg/cpr	Resistance to gastric juice at pH 1,2 ² (minutes)	Disintegration time at pH 6,8 ² (minutes)
031 (20/0)	0,34	0,44	39,87	32,00	-----
031A (25/3)	0,45	0,66	40,32	43,00	-----
031B (25/6)	0,53	0,72	39,99	45,00	-----
031C (25/12)	0,67	0,66	39,71	41,00	-----
¹ Temperature (°C)/time (months); ² Disintegration test according to USP current edition.					

EP 2 598 122 B1

EXAMPLE 6: 200 mg gastroresistant Ibuprofen tablets

[0114]

A. Ibuprofen	200,00 mg
B Magnesium oxide	70,00 mg
C. Magnesium hydroxide	100,00 mg
D. Xylitol	50,00 mg
E. Calcium carbonate	100,00 mg
F. Microcrystalline cellulose	60,00 mg
G. Magnesium stearate	20,00 mg
H. Stearic acid	40,00 mg
Total core weight	570,00 mg
I. Arginine Shellac	30,00 mg
L. Sodium starch glycolate	6,0 mg
M. Titanium dioxide	5,00 mg
N. Talc	10,00 mg
O. Triethyl citrate	5,00 mg
P. Precipitated silica	2,00 mg
Q. Yellow tartrazine	0,050 mg
Total tablet weight	628,05 mg

[0115] The cores, due to the presence of oxides and carbonate, are characterised by having a basic pH, so as to test the behaviour of the film on this type of cores.

Table 11

Stress test of Batches 006 and 019- 200 mg ibuprofen tablets (quali/quantitative composition of Example 6)					
Batch (T/t) ¹	Humidity % (K.F.)	Total impurities	Count mg/cpr	Resistance to gastric juice at pH 1,2 ² (minutes)	Disintegration time at pH 6,8 ² (minutes)
006 (20/0)	0,78	0,76	210,24	60,00	25,00
006A (40/1)	0,87	0,87	211,22	60,00	24,00
006B (40/3)	0,98	0,96	209,21	60,00	27,00
006C (40/6)	0,99	0,88	208,99	60,00	24,00
019 (20/0)	0,67	0,88	208,09	60,00	24,00
019A (40/1)	0,76	1,09	207,34	60,00	24,00
019B (40/3)	0,86	0,96	206,71	60,00	26,00
019C (40/6)	0,87	1,08	207,12	60,00	27,00
¹ Temperature (°C)/time (months); ² Disintegration test according to USP current edition.					

[0116] The data in Table 11 shows that in tablets with base film-coated cores with the presence of sodium starch glycolate in the film, the disintegration times at pH 6.8 are within specifications according to the disintegration test described in USP current edition and the variation of the disintegration again at pH 6.8 is constant over time after the

EP 2 598 122 B1

samples are conserved at 40 °C for 6 months.

Table 12

Shelf life of Batch 032- 200 mg ibuprofen tablets (quali/quantitative composition of Example 6)					
Batch (T/t) ¹	Humidity % (K.F.)	Total impurities	Count mg/cpr	Resistance to gastric juice at pH 1,2 ² (minutes)	Disintegration time at pH 6,8 ² (minutes)
032 (20/0)	0,54	0,76	209,19	60,00	25,00
032A (25/3)	0,66	1,00	208,36	60,00	29,00
032B (25/6)	0,73	0,94	207,95	60,00	29,00
032C (25/12)	0,79	1,12	206,42	60,00	34,00
¹ Temperature (°C)/time (months); ² Disintegration test according to USP current edition.					

EXAMPLE 7: 200 mg gastroresistant Ibuprofen tablets without sodium starch glycolate

[0117]

A. Ibuprofen	200,00 mg
B. Magnesium oxide	70,00 mg
C. Magnesium hydroxide	100,00 mg
D. Xylitol	50,00 mg
E. Calcium carbonate	100,00 mg
F. Microcrystalline cellulose	60,00 mg
G. Magnesium stearate	20,00 mg
H. Stearic acid	40,00 mg
Total core weight	570,00 mg
1. Arginine Shellac	30,00 mg
L. Titanium dioxide	5,00 mg
M. Talc	10,00mg
N. Triethyl citrate	5,00 mg
O. Precipitated silica	2,00 mg
P. Yellow tartrazine	0,050 mg
Total tablet weight	622,05 mg

Table 13

Stress test of Batches 007 and 020- 200 mg ibuprofen tablets (quali/quantitative composition of Example 7)					
Batch (T/t) ¹	Humidity % (K.F.)	Total impurities	Count mg/cpr	Resistance to gastric juice at pH 1,2 ² (minutes)	Disintegration time at pH 6,8 ² (minutes)
007 (20/0)	0,65	0,54	211,34	60,00	48,00
007A (40/1)	0,85	0,78	209,54	60,00	57,00
007B (40/3)	0,89	0,87	208,27	60,00	66,00

EP 2 598 122 B1

(continued)

Stress test of Batches 007 and 020- 200 mg ibuprofen tablets (quali/quantitative composition of Example 7)					
Batch (T/t) ¹	Humidity % (K.F.)	Total impurities	Count mg/cpr	Resistance to gastric juice at pH 1,2 ² (minutes)	Disintegration time at pH 6,8 ² (minutes)
007C (40/6)	0,88	0,78	209,19	60,00	73,00
020 (20/0)	0,54	0,65	208,34	60,00	52,00
020A (40/1)	0,76	0,68	207,11	60,00	62,00
020B (40/3)	0,79	0,78	207,00	60,00	73,00
020C (40/6)	0,82	0,82	206,02	60,00	78,00
¹ Temperature (°C)/time (months); ² Disintegration test according to USP current edition.					

[0118] The data in Table 13 shows that tablets with base film-coated cores without the presence of sodium starch glycolate in the coating film have considerably longer disintegration times at pH 6.8 (according to USP current edition) at time zero, and the variation thereof again at pH 6.8 is not constant over time after the samples have been conserved at 40 °C for 6 months.

Table 14

Shelf life of Batch 033- 200 mg ibuprofen tablets (quali/quantitative composition of example 7)					
Batch (T/t) ¹	Humidity % (K.F.)	Total impurities	Count mg/cpr	Resistance to gastric juice at pH 1,2 ² (minutes)	Disintegration time at pH 6,8 ² (minutes)
033 (20/0)	0,79	0,59	208,00	60,00	50,00
033A (25/3)	0,72	0,76	207,87	60,00	54,00
033B (25/6)	0,89	0,72	207,32	60,00	63,00
033C (25/12)	0,98	0,89	206,99	60,00	68,00
¹ Temperature (°C)/time (months); ² Disintegration test according to USP current edition.					

EXAMPLE 8: 1000 mg gastroresistant lactic ferments tablets

[0119]

A. Lactic ferments	1000,00 mg
B Microcrystalline cellulose	70,00 mg
C. Glycerol behenate	100,00 mg
D. calcium phosphate dihydrate	150,00 mg
E. Magnesium stearate	20,00 mg
F. Stearic acid	40,00 mg
G. Hydrogenated fatty acid	40,00 mg
Total core weight	1420,00 mg
H. Arginine Shellac	30,00 mg
I. Sodium starch glycolate	6,0 mg
L. Titanium dioxide	5,00 mg
M. Talc	10,00 mg
N. Triethyl citrate	5,00 mg

EP 2 598 122 B1

(continued)

O. Precipitated silica	2,00 mg
P. Yellow tartrazine	0,050 mg
Total tablet weight	1478,05 mg

Table 15

Stress test of Batches 008 and 021- 1000 mg lactic ferments tablets (quali/quantitative composition of Example 8)					
Batch (T/t) ¹	Humidity % (K.F.)	Total impurities	Count mg/cpr	Resistance to gastric juice at pH 1,2 ² (minutes)	Disintegration time at pH 6,8 ² (minutes)
008 (20/0)	0,35	3,54	5,00 ml	60,00	28,00
008A (40/1)	0,23	12,78	2,00 ml	60,00	27,00
008B (40/3)	0,19	24,87	0,5 ml	60,00	26,00
008C (40/6)	0,18	35,78	0,1 ml	60,00	29,00
021 (20/0)	0,40	3,21	5,60 ml	60,00	30,00
021A (40/1)	0,37	14,09	2,30 ml	60,00	24,00
021B (40/3)	0,39	25,98	0,73 ml	60,00	27,00
021C (40/6)	0,42	37,45	0,23 ml	60,00	32,00
¹ Temperature (°C)/time (months); ² Disintegration test according to USP current edition.					

[0120] The data in Table 15 shows that, for film-coated lactic ferments tablets with the presence of sodium starch glycolate in the film, the disintegration times at pH 6.8 are within specifications according to the disintegration test described in USP current edition and the variation of the disintegration again at pH 6.8 is constant over time after the samples are conserved at 40 °C for 6 months.

Table 16

Shelf life of Batch 034- 1000 mg lactic ferments tablets (quali/quantitative composition of Example 8)					
Batch (T/t) ¹	Humidity % (K.F.)	Total impurities	Count mg/cpr	Resistance to gastric juice at pH 1,2 ² (minutes)	Disintegration time at pH 6,8 ² (minutes)
034 (20/0)	0,36	4,67	5,80 ml	60,00	29,00
034A (25/3)	0,65	6,45	4,80 ml	60,00	28,00
034B (25/6)	0,46	7,76	3,90 ml	60,00	32,00
034C (25/12)	0,59	13,03	3,60 ml	60,00	33,00
¹ Temperature (°C)/time (months); ² Disintegration test according to USP current edition.					

EXAMPLE 9: 1000 mg gastroresistant lactic ferments tablets without sodium starch glycolate

[0121]

A. Live lactic ferments	1000,00 mg
-------------------------	------------

EP 2 598 122 B1

(continued)

B Microcrystalline cellulose	70,00 mg
C. Glycerol behenate	100,00 mg
D. calcium phosphate dihydrate	150,00 mg
E. Magnesium stearate	20,00 mg
F. Stearic acid	40,00 mg
G. Hydrogenated fatty acid	40,00 mg
Total core weight	1420,00 mg
H. Arginine Shellac	30,00 mg
I. Titanium dioxide	5,00 mg
L. Talc	10,00 mg
M. Triethyl citrate	5,00 mg
N. Precipitated silica	2,00 mg
O. Yellow tartrazine	0,050 mg
Total tablet weight	1518,05 mg

Table 17

Stress test of Batches 009 and 022- 1000 mg lactic ferments tablets without sodium starch glycolate (quali/quantitative composition of Example 9)					
Batch (T/t) ¹	Humidity % (K.F.)	Total impurities	Count mg/cpr	Resistance to gastric juice at pH 1,2 ² (minutes)	Disintegration time at pH 6,8 ² (minutes)
009 (20/0)	0,43	3,78	5,00 ml	60,00	38,00
009A (40/1)	0,33	15,78	2,30 ml	60,00	48,00
009 (40/3)	0,34	27,17	0,6 ml	60,00	56,00
009C (40/6)	0,22	37,79	0,2 ml	60,00	69,00
022 (20/0)	0,56	4,89	5,50 ml	60,00	45,00
022A (40/1)	0,49	15,81	2,98 ml	60,00	58,00
022B (40/3)	0,52	30,56	0,78 ml	60,00	69,00
022C (40/6)	0,44	40,52	0,45 ml	60,00	76,00
¹ Temperature (°C)/time (months); ² Disintegration test according to USP current edition.					

[0122] The data in Table 17 shows that film-coated lactic ferments tablets without the presence of sodium starch glycolate in the film have considerably longer disintegration times at pH 6.8 (according to USP current edition) at time zero, and the variation thereof again at pH 6.8 is not constant over time after the samples have been conserved at 40 °C for 6 months.

EP 2 598 122 B1

Table 18

Shelf life of Batch 035- 1000 mg lactic ferments tablets without sodium starch glycolate (quali/quantitative composition of Example 9)					
Batch (T/t) ¹	Humidity % (K.F.)	Total impurities	Count mg/cpr	Resistance to gastric juice at pH 1,2 ² (minutes)	Disintegration time at pH 6,8 ² (minutes)
035 (20/0)	0,45	4,34	5,50 ml	60,00	46,00
035A (25/3)	0,43	7,23	4,98 ml	60,00	48,00
035B (25/6)	0,62	9,45	4,29 ml	60,00	59,00
035C (25/12)	0,63	14,23	3,75 ml	60,00	64,00
¹ Temperature (°C)/time (months); ² Disintegration test according to USP current edition.					

EXAMPLE 10: 11.0 mg per tablet gastroresistant NADH tablet

[0123]

DESCRIPTION OF THE COMPONENTS	AMOUNT PER TABLET	
Active ingredient		
A) NADH	mg	11,00
B) Microcrystalline cellulose	mg	7,00
C) Sorbitol	mg	26,0
D) Glycerol behenate	mg	2,00
E) Magnesium oxide	mg	8,0
F) Magnesium stearate	mg	0,50
G) Calcium carbonate	mg	1,00
Weight of the core	mg	55,50
H) Arginine schellac	mg	2,00
I) Sodium starch glycolate	mg	0,20
L) Titanium dioxide	mg	0,10
M) Colloidal silica, anhydrous	mg	0,20
N) Talc	mg	0,20
O) Triethyl citrate	mg	0,15
Overall weight of the coated tablets	mg	58,35

Table 19

Stress test of Batches 010 and 023- 11,0 mg NADH tablets (quali/quantitative composition of Example 10)					
Batch (T/t) ¹	Humidity % (K.F.)	NAD ² (%)	NADH	Resistance to gastric juice at pH 1,2 ² (minutes)	Disintegration time at pH 6,8 ² (minutes)
010 (20/0)	3,40	1,41	10,43	60,00	28,00
010A (40/1)	3,19	2,03	10,98	60,00	28,00

EP 2 598 122 B1

(continued)

Stress test of Batches 010 and 023- 11,0 mg NADH tablets (quali/quantitative composition of Example 10)					
Batch (T/t) ¹	Humidity % (K.F.)	NAD ² (%)	NADH	Resistance to gastric juice at pH 1,2 ² (minutes)	Disintegration time at pH 6,8 ² (minutes)
010B (40/3)	3,44	2,43	9,21	60,00	26,00
010C (40/6)	2,93	3,61	9,21	60,00	29,00
023 (20/0)	3,89	1,09	10,87	60,00	23,00
023A (40/1)	4,19	1,93	9,98	60,00	25,00
023B (40/3)	3,87	2,04	9,00	60,00	29,00
023C (40/6)	3,91	3,32	8,95	60,00	28,00
¹ Temperature (°C)/time (months); ² Disintegration test according to USP current edition;					

[0124] The data in Table 19 shows that, for 11 mg film-coated NADH tablets with the presence of sodium starch glycolate in the film, the disintegration times at pH 6.8 are within specifications according to the disintegration test described in USP current edition and the variation of the disintegration again at pH 6.8 is constant over time after the samples are conserved at 40 °C for 6 months.

Table 20

Shelf life of Batch 036- 11,0 mg NADH tablets (quali/quantitative composition of Example 10)					
Batch (T/t) ¹	Humidity % (K.F.)	NAD ² (%)	NADH	Resistance to gastric juice at pH 1,2 ² (minutes)	Disintegration time at pH 6,8 ² (minutes)
036 (20/0)	3,65	1,65	10,47	60,00	26,00
036A (25/3)	4,57	2,09	10,08	60,00	29,00
036B (25/6)	4,77	2,14	9,89	60,00	29,00
036C (25/12)	4,21	2,67	8,56	60,00	30,00
¹ Temperature (°C)/time (months); ² Disintegration test according to USP current edition.					

EXAMPLE 11: 5.5 mg gastroresistant NADH tablets

[0125]

DESCRIPTION OF THE COMPONENTS	AMOUNT PER CPR	
Active ingredient		
A) NADH	Mg	5,50
B) Microcrystalline cellulose	Mg	7,00
C) Sorbitol	Mg	20,0
D) Glycerol behenate	Mg	2,00
E) Magnesium oxide	Mg	14,00

EP 2 598 122 B1

(continued)

DESCRIPTION OF THE COMPONENTS	AMOUNT PER CPR	
Active ingredient		
F) Magnesium stearate	Mg	0,50
G) Calcium carbonate	Mg	1,00
Weight of the core	Mg	50,00
H) Arginine schellac	Mg	2,00
I) Sodium starch glycolate	Mg	0,20
L) Titanium dioxide	Mg	0,10
M) Colloidal silica, Anhydrous	Mg	0,20
N) Talc	mg	0,20
O) Triethyl citrate	mg	0,15
Overall weight of the coated tablets	mg	52,85

Table 21

Stress test of Batches 011 and 024- 5,5 mg NADH tablets (quali/quantitative composition of Example 11)					
Batch (T/t) ¹	Humidity % (K.F.)	NAD ² (%)	NADH	Resistance to gastric juice at pH 1,2 ² (minutes)	Disintegration time at pH 6,8 ² (minutes)
011 (20/0)	3,77	2.11	5,43	60,00	32,00
011A (40/1)	4,19	2,53	5,18	60,00	34,00
011B (40/3)	4,34	2,99	4,56	60,00	29,00
011C (40/6)	3,99	3,91	4,06	60,00	31,00
024 (20/0)	3,43	2.43	5,32	60,00	30,00
024A (40/1)	4,78	2,87	4,98	60,00	31,00
024B (40/3)	6,09	3,43	4,32	60,00	27,00
024C (40/6)	5,32	3,76	4,26	60,00	32,00
¹ Temperature (°C)/time (months); ² Disintegration test according to USP current edition;					

[0126] The data in Table 21 shows that, for film-coated NADH tablets of different dosage to 5,5 mg with the presence of sodium starch glycolate in the film, the disintegration times at pH 6.8 are within specifications according to the disintegration test described in USP current edition and the variation of the disintegration again at pH 6.8 is constant over time after the samples are conserved at 40°C for 6 months.

EP 2 598 122 B1

Table 22

Shelf life of Batch 037 5,5 mg NADH tablets (quali/quantitative composition of Example 11)					
Batch (T/t) ¹	Humidity % (K.F.)	NAD ² (%)	NADH	Resistance to gastric juice at pH 1,2 ² (minutes)	Disintegration time at pH 6,8 ² (minutes)
037 (20/0)	3,87	2,09	5,12	60,00	31,00
037A (25/3)	3,99	2,03	5,00	60,00	35,00
037B (25/6)	4,11	2,67	4,78	60,00	29,00
037C (25/12)	4,89	2,98	4,66	60,00	33,00
¹ Temperature (°C)/time (months); ² Disintegration test according to USP current edition.					

EXAMPLE 12: 11,0 mg/tablet gastroresistant NADH tablets

[0127]

DESCRIPTION OF THE COMPONENTS	AMOUNT PER TABLET	
Active ingredient		
A) NADH	mg	11,00
B) Microcrystalline cellulose	mg	7,00
C) Sorbitol	mg	26,0
D) Glycerol behenate	mg	2,00
E) Magnesium oxide	mg	8,0
F) Magnesium stearate	mg	0,50
G) Calcium carbonate	mg	1,00
Weight of the core	mg	55,50
H) Arginine schellac	mg	2,00
I) Titanium dioxide	mg	0,10
L) Colloidal silica, anhydrous	mg	0,20
M) Talc	mg	0,20
N) Triethyl citrate	mg	0,15
Overall weight of the coated tablets	mg	58,35

Table 23

Stress test of Batches 012 and 025- 11,0 mg NADH tablets without sodium starch glycolate (quali/quantitative composition of Example 12)					
Batch (T/t) ¹	Humidity % (K.F.)	NAD ² (%)	NADH	Resistance to gastric juice at pH 1,2 ² (minutes)	Disintegration time at pH 6,8 ² (minutes)
012 (20/0)	3,89	1,71	10,78	60,00	43,00
012A (40/1)	3,90	2,53	10,12	60,00	47,00

EP 2 598 122 B1

(continued)

Stress test of Batches 012 and 025- 11,0 mg NADH tablets without sodium starch glycolate (quali/quantitative composition of Example 12)					
Batch (T/t) ¹	Humidity % (K.F.)	NAD ² (%)	NADH	Resistance to gastric juice at pH 1,2 ² (minutes)	Disintegration time at pH 6,8 ² (minutes)
012B (40/3)	4,21	2,87	9,45	60,00	59,00
012C (40/6)	3,93	3,89	9,09	60,00	67,00
025 (20/0)	4,42	1,21	10,28	60,00	49,00
025A (40/1)	4,23	2,98	10,00	60,00	53,00
025B (40/3)	4,76	3,56	9,21	60,00	66,00
025C (40/6)	4,02	4,82	9,00	60,00	72,00
¹ Temperature (°C)/time (months); ² Disintegration test according to USP current edition;					

[0128] The data in Table 23 shows that 11 mg film-coated NADH tablets without the presence of sodium starch glycolate in the film have considerably longer disintegration times at pH 6.8 (according to USP current edition) at time zero, and the variation thereof again at pH 6.8 is not constant over time after the samples have been conserved at 40 °C for 6 months.

Table 24

Shelf life of Batch 038 11,0 mg NADH tablets without sodium starch glycolate (quali/quantitative composition of Example 12)					
Batch (T/t) ¹	Humidity % (K.F.)	NAD ² (%)	NADH	Resistance to gastric juice at pH 1,2 ² (minutes)	Disintegration time at pH 6,8 ² (minutes)
038 (20/0)	3,93	1,11	10,13	60,00	45,00
038A (25/3)	4,03	2,18	10,01	60,00	49,00
038B (25/6)	4,45	2,53	9,71	60,00	56,00
038C (25/12)	4,92	2,84	9,54	60,00	62,00
¹ Temperature (°C)/time (months); ² Disintegration test according to USP current edition.					

EXAMPLE 13: 5.5 mg Gastroresistant NADH tablets

[0129]

DESCRIPTION OF THE COMPONENTS	AMOUNT PER TABLET	
Active ingredient		
A) NADH	mg	5.50
B) Microcrystalline cellulose	mg	7.00
C) Sorbitol	mg	20.0
D) Glycerol behenate	mg	2.00
E) Magnesium oxide	mg	14.00
F) Magnesium stearate	mg	0.50
G) Calcium carbonate	mg	1.00

EP 2 598 122 B1

(continued)

DESCRIPTION OF THE COMPONENTS	AMOUNT PER TABLET	
Active ingredient		
Weight of the core	mg	50.00
H) Arginine schellac	mg	2.00
I) Titanium dioxide	mg	0.10
L) Colloidal silica, anhydrous	mg	0.20
M) Talc	mg	0.20
N) Triethyl citrate	mg	0.15
Overall weight of the coated tablets	mg	52.85

Table 25

Stress test of Batches 013 and 026- 5,5 mg NADH tablets without sodium starch glycolate (quali/quantitative composition of Example 13)					
Batch (T/t) ¹	Humidity % (K.F.)	NAD ² (%)	NADH	Resistance to gastric juice at pH 1,2 ² (minutes)	Disintegration time at pH 6,8 ² (minutes)
013 (20/0)	3,97	2,00	5,13	60,00	42,00
013A (40/1)	4,01	2,33	5,48	60,00	54,00
013B (40/3)	4,24	2,59	4,34	60,00	69,00
013C (40/6)	3,66	3,81	4,16	60,00	71,00
026 (20/0)	4,54	2,54	5,32	60,00	51,00
026A (40/1)	4,32	3,65	4,99	60,00	62,00
026B (40/3)	4,67	3,09	4,54	60,00	71,00
026C (40/6)	5,17	3,41	4,08	60,00	78,00
¹ Temperature (°C)/time (months); ² Disintegration test according to USP current edition;					

[0130] The data in Table 25 shows that 5,5 mg film-coated NADH tablets without the presence of sodium starch glycolate in the film, have considerably longer disintegration times at pH 6.8 (according to USP current edition) at time zero, and the variation thereof again at pH 6.8 is not constant over time after the samples have been conserved at 40 °C for 6 months.

Table 26

Shelf life of Batch 039- 5,5 mg NADH tablets without sodium starch glycolate (quali/quantitative composition of Example 13)					
Batch (T/t) ¹	Humidity % (K.F.)	NAD ² (%)	NADH	Resistance to gastric juice at pH 1,2 ² (minutes)	Disintegration time at pH 6,8 ² (minutes)
039 (20/0)	3,98	1,94	5,19	60,00	50,00
039A (25/3)	4,62	2,45	5,34	60,00	57,00
039B (25/6)	4,27	2,89	4,84	60,00	60,00
039C (25/12)	4,89	3,05	4,68	60,00	64,00
¹ Temperature (°C)/time (months); ² Disintegration test according to USP current edition.					

[0131] From the stability data at 40°C and 75% R.H. (stress test) and from the stability data at 25°C and 60% R.H. (shelf life) it is possible to observe that all of the batches examined having sodium starch glycolate in the coating film

EP 2 598 122 B1

have considerably shorter disintegration times at time zero with respect to those without sodium starch glycolate.

[0132] After six months the samples with sodium starch glycolate had not undergone a difference in the disintegration test evaluated as disintegration time at pH 6,8. On the other hand, after six months the samples without sodium starch glycolate had undergone a substantial difference in the disintegration test evaluated as disintegration time at pH 6,8.

[0133] The sample with a different superdisintegrant does not pass the test at acidic pH due to the different behaviour that it has with respect to sodium starch glycolate.

[0134] Moreover, from the stability at 25°C and 60% R.H. (shelf life) it can be observed that after twelve months the samples with sodium starch glycolate had not undergone a difference in the disintegration test evaluated as disintegration time at pH 6,8, whereas on the other hand after twelve months the samples without sodium starch glycolate had undergone a substantial difference in the disintegration test evaluated as disintegration time at pH 6,8.

[0135] The sample with a different superdisintegrant does not pass the test at acidic pH due to the different behaviour that it has with respect to sodium starch glycolate.

EXAMPLE 14: 200 mg gastroresistant Ibuprofen type 0 capsules

[0136]

A. Ibuprofen	200,00 mg
B Mannitol	70,00 mg
C. Maltodextrine	100,00 mg
D. Xylitol	50,00 mg
E. Microcrystalline cellulose	60,00 mg
F. Magnesium stearate	20,00 mg
G. Stearic acid	40,00 mg
Total core weight	470,00 mg
H. Arginine Shellac	30,00 mg
I. Sodium starch glycolate	6,0 mg
L. Titanium dioxide	5,00 mg
M. Talc	10,00 mg
N. Triethyl citrate	5,00 mg
O. Precipitated silica	2,00 mg
P. Yellow tartrazine	0,050 mg
Total tablet weight	528,05 mg

Table 27

Stress test of Batches 040 and 041- 200 mg ibuprofen capsules (quali/quantitative composition of Example 14)					
Batch (T/t) ¹	Humidity % (K.F.)	Total impurities	Amount mg/cpr	Resistance to gastric juice at pH 1,2 ² (minutes)	Disintegration time at pH 6,8 ² (minutes)
040 (20/0)	0,34	0,88	209,56	60,00	29,00
040A (40/1)	0,43	0,98	209,00	60,00	27,00
040B (40/3)	0,54	0,93	208,92	60,00	28,00
040C (40/6)	0,65	0,76	208,69	60,00	28,00
041 (20/0)	0,44	0,70	208,99	60,00	29,00
041 A (40/1)	0,55	0,99	208,94	60,00	28,00

EP 2 598 122 B1

(continued)

Stress test of Batches 040 and 041- 200 mg ibuprofen capsules (quali/quantitative composition of Example 14)					
Batch (T/t) ¹	Humidity % (K.F.)	Total impurities	Amount mg/cpr	Resistance to gastric juice at pH 1,2 ² (minutes)	Disintegration time at pH 6,8 ² (minutes)
041B (40/3)	0,51	0,95	209,32	60,00	29,00
041C (40/6)	0,49	0,88	208,82	60,00	30,00
¹ Temperature (°C)/time (months); ² Disintegration test according to USP current edition.					

[0137] The data in Table 27 shows that in capsules with films with the presence of sodium starch glycolate in the film, the disintegration times at pH 6.8 are within specifications according to the disintegration test described in USP current edition and the variation of the disintegration again at pH 6.8 is constant over time after the samples are conserved at 40 °C for 6 months.

Table 28

Shelf life of Batch 042- 200 mg ibuprofen capsules (quali/quantitative composition of Example 14)					
Batch (T/t) ¹	Humidity % (K.F.)	Total impurities	Count mg/cpr	Resistance to gastric juice at pH 1,2 ² (minutes)	Disintegration time at pH 6,8 ² (minutes)
042 (20/0)	0,66	0,88	208,68	60,00	29,00
042A (25/3)	0,73	1,12	208,96	60,00	24,00
042B (25/6)	0,62	0,98	208,21	60,00	26,00
042C (25/12)	0,59	1,09	207,92	60,00	32,00
¹ Temperature (°C)/time (months); ² Disintegration test according to USP current edition.					

EXAMPLE 15: 200 mg gastroresistant Ibuprofen capsules without sodium starch glycolate

[0138]

A. Ibuprofen	200,00 mg
B Mannitol	70,00 mg
C. Maltodextrine	100,00 mg
D. Xylitol	50,00 mg
E. Microcrystalline cellulose	60,00 mg
F. Magnesium stearate	20,00 mg
G. Stearic acid	40,00 mg
Total core weight	470,00 mg
H. Arginine Shellac	30,00 mg
I. Titanium dioxide	5,00 mg
L. Talc	10,00 mg
M. Triethyl citrate	5,00 mg
N. Precipitated silica	2,00 mg
O. Yellow tartrazine	0,050 mg
Total tablet weight	522,05 mg

EP 2 598 122 B1

Table 29

Stress test of Batches 043 and 044- 200 mg ibuprofen capsules (quali/quantitative composition of Example 15)					
Batch (T/t) ¹	Humidity % (K.F.)	Total impurities	Count mg/cpr	Resistance to gastric juice at pH 1,2 ² (minutes)	Disintegration time at pH 6,8 ² (minutes)
043 (20/0)	0,49	0,34	210,54	60,00	49,00
043A (40/1)	0,43	0,33	209,98	60,00	58,00
043B (40/3)	0,55	0,45	209,87	60,00	73,00
043C (40/6)	0,36	0,68	208,87	60,00	83,00
044 (20/0)	0,65	0,43	209,67	60,00	59,00
044A (40/1)	0,43	0,44	209,13	60,00	72,00
044B (40/3)	0,34	0,54	209,07	60,00	78,00
044C (40/6)	0,23	0,62	208,32	60,00	88,00
¹ Temperature (°C)/time (months); ² Disintegration test according to USP current edition.					

[0139] The data in Table 29 shows that film-coated capsules without the presence of sodium starch glycolate in the coating film have considerably longer disintegration times at pH 6.8 (according to USP current edition) at time zero, and the variation thereof again at pH 6.8 is not constant over time after the samples have been conserved a 40 °C for 6 months.

Table 30

Shelf life of Batch 045- 200 mg ibuprofen capsules (quali/quantitative composition of Example 15)					
Batch (T/t) ¹	Humidity%	Total impurities	Count mg/cpr	Resistance to gastric juice at pH 1,2 ² (minutes)	Disintegration time at pH 6,8 ² (minutes)
045 (20/0)	0,45	0,69	209,34	60,00	54,00
045A (25/3)	0,44	0,56	209,02	60,00	57,00
045B (25/6)	0,36	0,62	208,90	60,00	73,00
045C (25/12)	0,28	0,78	208,99	60,00	88,00
¹ Temperature (°C)/time (months); ² Disintegration test according to USP current edition.					

EXAMPLE 16: 400 mg IONE SAME/Cpr gastroresistant tablets

[0140]

A. SAME sulphate p-toluenesulfonate	830,00 mg
B. Mannitol	42,000 mg
C. Silica (Aerosil®)	2,00 mg
D. Anhydrous microcrystalline cellulose 112	114,00 mg
E. Vegetable magnesium stearate	12,00 mg

EP 2 598 122 B1

(continued)

Total core weight	1000,00 mg
F. Arginine Shellac®	21,00 mg
G. Titanium dioxide	2,62 mg
H. Talc	7,87 mg
I. Triethyl citrate	7,87 mg
L. Sodium starch glycolate (explotab)	1,50 mg
M. Silica (Aerosil®)	2,62 mg
Total tablet weight	1043,48 mg

Production of the cores:

1.1. Mixing

[0141] The work environment is conditioned to a temperature of 20 °C and to a relative humidity value equal to about 20% R.H. Then A, B, C, D, and E are transferred in the amounts indicated in Example 16 into the "Viani" biconical mixer leaving it under stirring for about 30 minutes. At the end of such an operation, the resulting mixture is transferred into dry recipients, still controlling humidity and temperature.

[0142] Then comes the direct compression of the mixture of powder through a rotary machine equipped with oblong punches of 19,0 X 8,8 mm adjusting the weight to 1050 mg/cpr and the compression force to about 35 KP. The tablets produced have a hardness of between 33 and 37 Kp.

[0143] Friability: ≤ 1,0%; disintegration time: ≤ 15 minutes (measured according to the method described in U.S.P. Current edition.)

[0144] Humidity according to K.F. ≤ 1,5%.

[0145] The stability tests on the uncoated cores were carried out just at 40 °C and 75 % R.H for six months and for a single batch since they are not a finished product. The samples were conserved in capped and sealed glass flasks to simulate the final packaging (alu/alu blister pack).

Table 31

Batch 001- 400 mg uncoated ion/cpr cores (Example 16)				
Batch (T/t) ¹	Humidity % (K.Fischer)	Total impurities ² (%)	SAMe ³	S,S %
001 (20/0)	1,17	0,54	408,45	82,03
001A (40/1)	1,28	0,67	406,97	78,12
001B (40/3)	1,29	1,49	400,22	70,84
001C (40/6)	1,33	2,58	399,54	66,12
¹ Temperature (°C)/time (months); ² total impurities; ³ SAMe sulphate p-toluenesulfonate (mg/cpr).				

[0146] The tablets resulting from the previous processing steps were film-coated in a coating pan.

Table 32

Stress test of Batches 002 and 003 - 400 mg SAMe sulphate p-toluenesulfonate tablets (quali/quantitative composition of Example 16)						
Batch (T/t) ¹	Humidity % (K.F.)	Total impurities	S,S %	Count mg/cpr	Resistance to gastric juice at pH 1,2 ² (minutes)	Disintegration time at pH 6,8 ² (minutes)
002 (20/0)	1,24	0,62	83,14	408,45	60,00	27,00
002A (40/1)	1,25	0,59	80,21	406,40	60,00	26,00
002B (40/3)	1,13	0,99	75,23	404,12	60,00	29,00

EP 2 598 122 B1

(continued)

Stress test of Batches 002 and 003 - 400 mg SAME sulphate p-toluenesulfonate tablets (quali/quantitative composition of Example 16)						
Batch (T/t) ¹	Humidity % (K.F.)	Total impurities	S,S %	Count mg/cpr	Resistance to gastric juice at pH 1,2 ² (minutes)	Disintegration time at pH 6,8 ² (minutes)
002C (40/6)	1,12	1,69	70,21	403,00	60,00	29,00
003 (20/0)	1,22	0,63	82,33	409,23	60,00	27,00
003A (40/1)	1,13	0,92	79,21	407,67	60,00	28,00
003B (40/3)	1,11	1,22	76,32	406,32	60,00	29,00
003C (40/6)	1,22	1,88	69,25	404,56	60,00	30,00
¹ Temperature (°C)/time (months); ² Disintegration test according to USP current edition.						

Table 33

Shelf life of Batch 004- 400 mg SAME sulphate p-toluenesulfonate tablets (quali/quantitative composition of Example 16)						
Batch (T/t) ¹	Humidity % (K.F.)	Total impurities	S,S	Count mg/cpr	Resistance to gastric juice at pH 1,22 (minutes)	Disintegration time at pH 6,82 (minutes)
004(20/0)	1,21	0,53	82,16	408,37	60,00	30,00
004A (25/3)	1,23	0,64	81,92	408,14	60,00	30,00
004B (25/6)	1,46	0,62	81,63	407,12	60,00	29,00
004C (25/12)	1,34	0,87	81,20	406,22	60,00	29,00
¹ Temperature (°C)/time (months); ² Disintegration test according to USP current edition.						

[0147] The data in Tables 32 and 33 shows that both the samples subjected to stress testing and those conserved at room temperature, in the presence of sodium starch glycolate in the coating film have disintegration times at pH 6.8 within specifications according to the disintegration test described in USP current edition and the variation of the disintegration again at pH 6.8 is constant over time.

[0148] The data in Tables 32 and 33 also shows that the samples of SAME sulphate p-toluenesulfonate subjected both to stress testing and conserved at room temperature have a greater stability with respect to the cores of the same example before coating with the film described in the present invention.

EXAMPLE 17: 400 mg IONE SAME/Cpr gastroresistant tablets

[0149]

A. SAME sulphate p-toluenesulfonate	830,00 mg
B. Mannitol	42,000 mg
C. Silica (Aerosil®)	2,00 mg
D. Anhydrous microcrystalline cellulose 112	114,00 mg
E. Vegetable magnesium stearate	12,00 mg

EP 2 598 122 B1

(continued)

Total core weight	1000,00 mg
F. Arginine Shellac®	21,00 mg
G. Titanium dioxide	2,62 mg
H. Talc	7,87 mg
I. Triethyl citrate	7,87 mg
L. Silica (Acrosit®)	2,62 mg
Total tablet weight	1041,98 mg

Table 34

Batch 005- 400 mg uncoated ion/cpr cores (Example 17)				
Batch (T/t) ¹	Humidity % (K.Fischer)	Total impurities ² (%)	SAMe ³	S,S %
005 (20/0)	1,37	0,46	408,45	82,33
005° (40/1)	1,24	0,57	406,47	72,42
005B (40/3)	1,41	1,75	404,25	67,11
005C (40/6)	1,39	2,79	402,74	60,15
¹ Temperatura (°C)/time (months); ² total impurities; ³ SAMe sulphate p-toluenesulfonate (mg/cpr).				

[0150] The tablets resulting from the processing steps like in Example 17 were film-coated in coating pan.

Table 35

Stress test of Batches 006 and 007 - 400 mg SAMe sulphate p-toluenesulfonate tablets (quali/quantitative composition of Example 17)						
Batch (T/t) ¹	Humidity% (K.F.)	Total impurities	S,S %	Count mg/cpr	Resistance to gastric juice at pH 1,2 ² (minutes)	Disintegration time at pH 6,8 ² (minutes)
006 (20/0)	1,43	0,55	83,34	408,90	60,00	29,00
006A (40/1)	1,35	0,79	80,00	407,12	60,00	37,00
006B (40/3)	1,33	0,89	72,53	403,89	60,00	40,00
006C (40/6)	1,32	1,89	68,21	402,45	60,00	71,00
007 (20/0)	1,42	0,53	82,11	408,54	60,00	39,00
007A (40/1)	1,33	0,82	78,11	406,89	60,00	49,00
007B (40/3)	1,43	1,02	74,92	405,21	60,00	59,00
007C (40/6)	1,37	2,12	69,00	402,23	60,00	62,00
¹ Temperature (°C)/time (months); ² Disintegration test according to USP current edition.						

EP 2 598 122 B1

Table 36

Shelf life of Batch 008- 400 mg SAME sulphate p-toluenesulfonate tablets (qual/quantitative composition of Example 17)						
Batch (T/t) ¹	Humidity % (K.F.)	Total impurities	S,S %	Count mg/cpr	Resistance to gastric juice at pH 1,2 ² (minutes)	Disintegration time at pH 6,8 ² (minutes)
008(20/0)	1,34	0,63	82,16	408,37	60,00	41,00
008A (25/3)	1,54	0,60	80,92	407,56	60,00	51,00
008B (25/6)	1,40	0,89	80,63	405,76	60,00	60,00
008C (25/12)	1,34	0,97	78,67	405,98	60,00	71,00
¹ Temperature (°C)/time (months); ² Disintegration test according to USP current edition.						

[0151] The data in Tables 35 and 36 shows that both the samples subjected to stress testing and those conserved at room temperature, in the absence of sodium starch glycolate in the coating film, have disintegration times at pH 6.8 outside specifications according to the disintegration test described in USP current edition and the variation of the disintegration again at pH 6.8 is not constant over time.

[0152] The data in Tables 35 and 36 also shows that the samples of SAME sulphate p-toluenesulfonate subjected both to stress testing and conserved at room temperature have a greater stability with respect to cores of the same example before coating with the film described in the present invention.

EXAMPLE 18: 200 mg IONE SAME/Cpr gastroresistant tablets

[0153]

A. SAME sulphate p-toluenesulfonate	415,40 mg
B. Anhydrous calcium chloride powder	23,40 mg
C. Silica (Aerosil®)	2,00 mg
D. Anhydrous microcrystalline cellulose 112	151,00 mg
E. Vegetable magnesium stearate	8,20 mg
Total core weight	600,00 mg
F. Arginine Shellac®	14,00 mg
G. Titanium dioxide	1,75 mg
H. Talc	5,25 mg
I. Triethyl citrate	5,25 mg
L. Sodium starch glycolate (explotab)	1,00 mg
M. Silica (Aerosi®)	1,75 mg
Total tablet weight	629,00 mg

Production of the cores: for the process refer to Example 16.

[0154]

Table 37

Batch 009- 200 mg uncoated ion/cpr cores (Example 18)				
Batch (T/t) ¹	Humidity % (K.Fischer)	Total impurities ² (%)	SAMe ³	S,S %
009 (20/0)	132	0,45	204.21	84,55

EP 2 598 122 B1

(continued)

Batch 009- 200 mg uncoated ion/cpr cores (Example 18)				
Batch (T/t) ¹	Humidity % (K.Fischer)	Total impurities ² (%)	SAMe ³	S,S %
009A (40/1)	1,29	0,70	204,01	82,21
009B (40/3)	1,35	1,51	202,32	78,32
009C (40/6)	1,36	1,91	201,00	72,43
¹ Temperature (°C)/time (months); ² total impurities; ³ SAMe sulphate p-toluenesulfonate (mg/cpr);				

[0155] The tablets resulting from the previous processing steps were film-coated in coating pan.

Table 38

Stress test of Batches 010 and 011 - 200 mg SAMe sulphate p-toluenesulfonate tablets (quali/quantitative composition of Example 18)						
Batch (T/t) ¹	Humidity % (K.F.)	Total impurities	S,S %	Count mg/cpr	Resistance to gastric juice at pH 1,22 (minutes)	Disintegration time at pH 6,82 (minutes)
010 (20/0)	1,11	0,54	83,22	206,76	60,00	30,00
010A (40/1)	1,33	0,78	81,19	205,64	60,00	29,00
010B (40/3)	1,22	0,98	79,42	204,82	60,00	28,00
010C (40/6)	1,54	1,23	77,34	203,99	60,00	29,00
011 (20/0)	1,22	0,53	82,33	207,71	60,00	27,00
011A (40/1)	1,23	0,69	81,67	206,19	60,00	29,00
011B (40/3)	1,25	0,88	78,34	205,92	60,00	30,00
011C (40/6)	1,12	1,28	77,24	204,98	60,00	29,00
¹ Temperature (°C)/time (months); ² Disintegration test according to USP current edition.						

Table 39

Shelf life of Batch 012- 200 mg SAMe sulphate p-toluenesulfonate tablets (quali/quantitative composition of Example 18)						
Batch (T/t) ¹	Humidity% (K.F.)	Total impurities	S,S %	Count mg/cpr	Resistance to gastric juice at pH 1,2 ² (minutes)	Disintegration time at pH 6.8 ² (minutes)
012(20/0)	1,39	0,57	83,00	206,89	60,00	30,00
012A (25/3)	1,32	0,65	82,21	205,76	60,00	30,00
012B (25/6)	1,28	0,82	78,39	204,00	60,00	27,00
012C (25/12)	1,35	1,23	76,14	203,92	60,00	29,00
¹ Temperature (°C)/time (months); ² Disintegration test according to USP current edition.						

[0156] The data in Tables 38 and 39 shows that both the samples subjected to stress testing and those conserved at room temperature, in the presence of sodium starch glycolate in the coating film, have disintegration times at pH 6.8 within specifications according to the disintegration test described in USP current edition and the variation of the disintegration again at pH 6.8 is constant over time.

[0157] The data in Tables 38 and 39 also shows that the stability of SAME sulphate p-toluenesulfonate on the samples subjected both to stress testing and conserved at room temperature have a greater stability with respect to cores of the same example before coating with the film described in the present invention.

EXAMPLE 19: 30 mg gastroresistant Lansoprazole capsules

[0158]

A. Lansoprazole	30,00 mg
B Microcrystalline cellulose	170,00 mg
C. Mannitol	80,00 mg
D. Sorbitol	150,00 mg
E. Silicon dioxide	2,00 mg
F. Magnesium stearate	2,00 mg
Net capsule weight	434,00 mg
G. Arginine Shellac	30,00 mg
H. Sodium starch glycolate	6,0 mg
I. Titanium dioxide	5,00 mg
L. Talc	10,00 mg
M. Triethyl citrate	5,00 mg
N. Precipitated silica	2,00 mg
Total capsule weight (including capsule weight)	692,00 mg

1. Mixing

[0159] The work environment is conditioned to a temperature of 25 °C and to a relative humidity value equal to about 40% R.H. Then A, B, C, D, E, F, G and H are transferred in the amounts indicated above, into the mixer, leaving it under stirring for about 30 minutes. At the end of such an operation, the resulting mixture is transferred into dry recipients, again controlling humidity and temperature.

2. Incapsulation

[0160] There is then the final encapsulation of the mixture through a Zanasi rotary machine equipped with a pre-compression station and producing capsules with net weight of about 492 mg. The capsules produced have a weight of between 470 and 510 ng .

3. Film-coating of the capsules

[0161] In a recipient having suitable dimensions the shellac with arginine base is dissolved at 60°C, the sodium starch glycolate is added and it is brought to 80°C until a solution is obtained with 20 % p/v of arginine schellac salt with 4% sodium starch glycolate in suspension. Thereafter, under constant stirring, the glycerol is added slowly. In another steel recipient again equipped with a stirrer the talc, the titanium dioxide, the precipitated silica and the curcumin are dispersed in 4,0 l of deionized water. The resulting suspension is poured into the arginine Shellac solution, washing the recipient with about 1,0 l of deionized water, then diluting with another 4,0 l of deionized water.

[0162] The enteric coating is carried out at a temperature of 45°C, once the gastroresistant coating is complete, it is left to dry for another 10 minutes again at 45°C. Finally, it is necessary to wait for the temperature to lower to 32-33°C so as to be able to start emptying the coating pan, taking care to conserve the capsules in suitable bags that are impermeable to humidity. All of the tests foreseen by the quality specifications are also carried out on them.

EP 2 598 122 B1

Table 40

Stress test of Batches 046 and 047 - 30 mg lansoprazole capsules (quali/quantitative composition of Example 19)					
Batch (T/t) ¹	Humidity % (K.F.)	Total impurities	Count mg/cps	Resistance to gastric juice at pH 1,2 ² (minutes)	Disintegration time at pH 6,8 ² (minutes)
046 (20/0)	0,45	0,21	30,6	60,00	22,00
046A (40/1)	0,44	0,22	30,5	60,00	22,00
046B (40/3)	0,65	0,23	30,3	60,00	19,00
046C (40/6)	0,55	0,21	30,2	60,00	19,00
047 (20/0)	0,65	0,22	30,4	60,00	20,00
047A (40/1)	0,66	0,26	30,2	60,00	20,00
047B (40/3)	0,76	0,31	29,9	60,00	22,00
047C (40/6)	0,68	0,32	29,8	60,00	22,00
¹ Temperature (°C)/time (months); ² Disintegration test according to USP current edition.					

[0163] The data in Table 40 shows that in the presence of sodium starch glycolate, the disintegration times at pH 6.8 are within specifications according to the disintegration test described in USP current edition and the variation of the disintegration again at pH 6.8 is constant over time after the samples are conserved at 40 °C for 6 months.

Table 41

Shelf life of Batch 048- 30 mg lansoprazole capsules (quali/quantitative composition of Example 19)					
Batch (T/t) ¹	Humidity % (K.F.)	Total impurities	Count mg/cps	Resistance to gastric juice at pH 1,2 ² (minutes)	Disintegration time at pH 6,8 ² (minutes)
048(20/0)	0,23	0,34	30,33	60,00	20,00
048A (25/3)	0,32	0,30	30,12	60,00	22,00
048B (25/6)	0,33	0,32	30,11	60,00	20,00
048C (25/12)	0,34	0,30	29,99	60,00	21,00
¹ Temperature (°C)/time (months); ² Disintegration test according to USP current edition.					

EXAMPLE 20: 30 mg gastroresistant Lansoprazole capsules

[0164]

A. Lansoprazole	30,00 mg
B Microcrystalline cellulose	176,00 mg
C. Mannitol	80,00 mg
D. Sorbitol	150,00 mg
E. Silicon dioxide	2,00 mg

EP 2 598 122 B1

(continued)

F. Magnesium stearate	2,00 mg
Net capsule weight	434,00 mg
G. Arginine Shellac	30,00 mg
H. Titanium dioxide	5,00 mg
I. Talc	10,00 mg
L. Triethyl citrate	5,00 mg
M. Precipitated silica	2,00 mg
Total capsule weight (including capsule weight)	692,00 mg

Table 42

Stress test of Batches 049 and 050- 30 mg lansoprazole capsules (quali/quantitative composition of Example 20)					
Batch (T/t) ¹	Humidity % (K.F.)	Total impurities	Count mg/cps	Resistance to gastric juice at pH 1,2 ² (minutes)	Disintegration time at pH 6,8 ² (minutes)
049 (20/0)	0,43	0,32	30,3	60,00	33,00
049A (40/1)	0,45	0,30	30,2	60,00	50,00
049B (40/3)	0,56	0,28	30,3	60,00	60,00
049C (40/6)	0,73	0,34	29,5	60,00	64,00
050 (20/0)	0,73	0,27	30,5	60,00	37,00
050A (40/1)	0,76	0,29	30,3	60,00	48,00
050B (40/3)	0,87	0,33	30,7	60,00	53,00
050C (40/6)	0,88	0,37	29,9	60,00	68,00
¹ Temperature (°C)/time (months); ² Disintegration test according to USP current edition.					

[0165] The data in Table 42 shows that in the absence of sodium starch glycolate, the disintegration times at pH 6.8 (according to USP current edition) are considerably longer at time zero, and the variation thereof again at pH 6.8 is not constant over time after the samples are conserved at 40 °C for 6 months.

Table 43

Shelf life of Batch 051- 30 mg lansoprazole capsules without sodium starch glycolate (quali/quantitative composition of Example 20)					
Batch (T/t) ¹	Humidity% (K.F.)	Total impurities	Count mg/cps	Resistance to gastric juice at pH 1,2 ² (minutes)	Disintegration time at pH 6,8 ² (minutes)
051 (20/0)	0,44	0,36	31,03	60,0	33,00
051A (25/3)	0,55	0,55	31,00	60,0	44,00
051B (25/6)	0,63	0,43	30,11	60,0	51,00

EP 2 598 122 B1

(continued)

Shelf life of Batch 051- 30 mg lansoprazole capsules without sodium starch glycolate (quali/quantitative composition of Example 20)					
Batch (T/t) ¹	Humidity% (K.F.)	Total impurities	Count mg/cps	Resistance to gastric juice at pH 1,2 ² (minutes)	Disintegration time at pH 6,8 ² (minutes)
051C (25/12)	0,65	0,35	29,89	60,0	64,00
¹ Temperature (°C)/time (months); ² Disintegration test according to USP current edition.					

EXAMPLE 21: 500 mg gastroresistant lactic ferments capsules

[0166]

A. Lactic ferments	500,00 mg
B Microcrystalline cellulose	20,00 mg
C. calcium phosphate dihydrate	50,00 mg
D. Magnesium stearate	20,00 mg
Net capsule weight	590,00 mg
E. Arginine Shellac	30,00 mg
F. Sodium starch glycolate	6,0 mg
G. Titanium dioxide	5,00 mg
H. Talc	10,00 mg
I. Triethyl citrate	5,00 mg
L. Precipitated silica	2,00 mg
Total capsule weight (including capsule weight)	648 mg

Table 44

Stress test of Batches 052 and 053- 500 mg lactic ferments capsules (quali/quantitative composition of Example 21)					
Batch (T/t) ¹	Humidity % (K.F.)	Total impurities	Count mg/cps	Resistance to gastric juice at pH 1,2 ² (minutes)	Disintegration time at pH 6,8 ² (minutes)
052 (20/0)	0,32	3,33	2,50 ml	60,00	20,00
052A (40/1)	0,28	11,45	1,10 ml	60,00	20,00
052B (40/3)	0,39	23,84	0,34 ml	60,00	21,00
052C (40/6)	0,38	38,48	0,02 ml	60,00	21,00
053 (20/0)	0,30	4,45	2,56 ml	60,00	20,00
053A (40/1)	0,57	13,45	1,20 ml	60,00	20,00
053B (40/3)	0,39	26,74	0,43 ml	60,00	22,00
053C (40/6)	0,45	36,75	0,03 ml	60,00	22,00
¹ Temperature (°C)/time (months); ² Disintegration test according to USP current edition.					

EP 2 598 122 B1

[0167] The data in Table 44 shows that, for film-coated lactic ferments capsules with the presence of sodium starch glycolate in the film, the disintegration times at pH 6.8 are within specifications according to the disintegration test described in USP current edition and the variation of the disintegration again at pH 6.8 is constant over time after the samples are conserved at 40 °C for 6 months.

Table 45

Shelf life of Batch 054 1000 mg lactic ferments capsules (quali/quantitative composition of Example 21)					
Batch (T/t) ¹	Humidity % (K.F.)	Total impurities	Count mg/cpr	Resistance to gastric juice at pH 1,2 ² (minutes)	Disintegration time at pH 6,8 ² (minutes)
054 (20/0)	0,33	3,67	2,80 ml	60,00	20,00
054A (25/3)	0,62	5,45	1,20 ml	60,00	28,00
054B (25/6)	0,41	8,76	0,90 ml	60,00	22,00
054C (25/12)	0,53	14,03	0,06 ml	60,00	23,00
¹ Temperature (°C)/time (months); ² Disintegration test according to USP current edition.					

EXAMPLE 22: 500 mg gastroresistant lactic ferments capsules without sodium starch glycolate

[0168]

A. Lactic ferments	500,00 mg
B Microcrystalline cellulose	26,00 mg
C. calcium phosphate dihydrate	50,00 mg
D. Magnesium stearate	20,00 mg
Net capsule weight	590,00 mg
E. Arginine Shellac	30,00 mg
F. Titanium dioxide	5,00 mg
G. Talc	10,00 mg
H. Triethyl citrate	5,00 mg
I. Precipitated silica	2,00 mg
Total capsule weight (including capsule weight)	648 mg

Table 46

Stress test of Batches 055 and 056 500 mg lactic ferments capsules without sodium starch glycolate (quali/quantitative composition of Example 22)					
Batch (T/t) ¹	Humidity % (K.F.)	Total impurities	Count mg/cpr	Resistance to gastric juice at pH 1,2 ² (minutes)	Disintegration time at pH 6,8 ² (minutes)
055 (20/10)	0,34	5,78	2,30 ml	60,00	32,00
055A (40/1)	0,36	18,38	1,30 ml	60,00	38,00
055B (40/3)	0,34	29,47	0,99 ml	60,00	46,00
055C (40/6)	0,56	38,99	0,02 ml	60,00	66,00
056 (20/0)	0,66	4,99	2,60 ml	60,00	35,00
056A (40/1)	0,40	16,86	1,68 ml	60,00	48,00
056B (40/3)	0,56	33,54	0,88 ml	60,00	59,00

EP 2 598 122 B1

(continued)

Stress test of Batches 055 and 056 500 mg lactic ferments capsules without sodium starch glycolate (quali/quantitative composition of Example 22)

Batch (T/t) ¹	Humidity % (K.F.)	Total impurities	Count mg/cpr	Resistance to gastric juice at pH 1,2 ² (minutes)	Disintegration time at pH 6,8 ² (minutes)
056C (40/6)	0,54	42,32	0,08 ml	60,00	66,00

¹ Temperature (°C)/time (months); ² Disintegration test according to USP current edition.

[0169] The data in Table 46 shows that the film-coated lactic ferments capsules without the presence of sodium starch glycolate in the film have considerably longer disintegration times at pH 6.8 (according to USP current edition) at time zero, and the variation thereof again at pH 6.8 is not constant over time after the samples have been conserved at 40 °C for 6 months.

Table 47

Shelf life of Batch 057 500 mg lactic ferments capsules without sodium starch glycolate (quali/quantitative composition of Example 22)

Batch (T/t) ¹	Humidity % (K.F.)	Total impurities	Count mg/cpr	Resistance to gastric juice at pH 1,2 ² (minutes)	Disintegration time at pH 6,8 ² (minutes)
057 (20/0)	0,34	6,00	2,30 ml	60,00	36,00
057A (25/3)	0,46	8,83	2,00 ml	60,00	48,00
057B (25/6)	0,68	10,35	1,89 ml	60,00	49,00
057C (25/12)	0,65	18,83	1,55 ml	60,00	62,00

¹ Temperature (°C)/time (months); ² Disintegration test according to USP current edition.

EXAMPLE 23: 11,0 mg NADH/gram gastroresistant pellets

[0170]

DESCRIPTION OF THE COMPONENTS	AMOUNT PER GRAM	
Active ingredient		
A) NADH	mg	11,00
B) Neutral saccharose pellets	mg	810,00
C) Sorbitol	mg	490,0
G) Talc	mg	40,00
Weight of the core pellets	mg	910,00
H) Arginine schellac	mg	50,00
I) Sodium starch glycolate	mg	2,00
L) Titanium dioxide	mg	10,00
M) Colloidal silica, anhydrous	mg	2,00
N) Talc	mg	20,00
O) Glycerol	mg	6,00
Overall weight of the pellets	mg	1000,00

EP 2 598 122 B1

Table 48

Stress test of Batches 058 and 059 11,0 mg NADH pellets (quali/quantitative composition of Example 23)					
Batch (T/t) ¹	Humidity % (K.F.)	NAD ² (%)	NADH	Resistance to gastric juice at pH 1,2 ² (minutes)	Disintegration time at pH 6,8 ² (minutes)
058 (20/0)	3,44	1,76	10,93	60,00	22,00
058A (40/1)	3,67	2,43	10,68	60,00	23,00
058B (40/3)	3,94	2,67	10,22	60,00	22,00
058C (40/6)	3,56	3,98	9,91	60,00	23,00
058 (2010)	3,34	1,59	10,89	60,00	27,00
058A (40/1)	4,56	1,73	10,45	60,00	25,00
058B (40/3)	3,97	2,54	10,311	60,00	23,00
058C (40/6)	3,78	3,22	9,65	60,00	24,00
¹ Temperature (°C)/time (months); ² Disintegration test according to USP current edition;					

[0171] The data in Table 48 shows that, for 11 mg film-coated NADH pellets with the presence of sodium starch glycolate in the film, the disintegration times at pH 6.8 are within specifications according to the disintegration test described in USP current edition and the variation of the disintegration again at pH 6.8 is constant over time after the samples are conserved at 40 °C for 6 months.

Table 49

Shelf life of Batch 059 11,0 mg NADH pellets (quali/quantitative composition of Example 23)					
Batch (T/t) ¹	Humidity % (K.F.)	NAD ² (%)	NADH	Resistance to gastric juice at pH 1,2 ² (minutes)	Disintegration time at pH 6,8 ² (minutes)
059 (20/0)	3,23	1,78	10,88	60,00	24,00
059A (25/3)	5,44	2,89	10,11	60,00	23,00
059B (25/6)	5,97	2,99	10,22	60,00	22,00
059C (25/12)	6,89	3,78	9,99	60,00	20,00
¹ Temperature (°C)/time (months); ² Disintegration test according to USP current edition.					

EXAMPLE 24: 400 mg IONE SAME/gram gastroresistant granulate

[0172]

A. SAME sulphate p-toluenesulfonate	830,00 mg
B. Sorbitol	42,000 mg
C. Silica (Aerosil®)	2,00 mg
D. Anhydrous microcrystalline cellulose 172	71,00 mg
E. Vegetable magnesium stearate	12,00 mg

EP 2 598 122 B1

(continued)

Total granule weight	957,00 mg
F. Arginine Shellac®	21,00 mg
G. Titanium dioxide	2,62 mg
H. Talc	7,87 mg
I. Triethyl citrate	7,87 mg
L. Sodium starch glycolate (explotab)	1,50 mg
M. Silica (Aerosil®)	2,14 mg
Total granule weight	1000,00 mg

[0173] Stress test of Batches 060 and 061 400 mg/ion per gram of SAM-e granulate with sodium starch glycolate in the film-coating (quali/quantitative composition of Example 24).

Table 50

Stress test of Batches 060 and 061 -400 mg SAME sulphate p-toluenesulfonate per gram granulates (quali/quantitative composition of Example 24)						
Batch (T/t) ¹	Humidity % (K.F.)	Total impurities	S,S%	Count mg/gr	Resistance to gastric juice at pH 1,2 ² (minutes)	Disintegration time at pH 6,8 ² (minutes)
060 (20/0)	1,00	0,34	82,84	405,85	60,00	20,00
060A (40/1)	1,05	0,43	80,00	404,40	60,00	20,00
060B (40/3)	1,10	0,56	74,73	402,12	60,00	20,00
060C (40/6)	1,02	1,23	72,91	400,40	60,00	19,00
061 (20/0)	1,02	0,67	82,93	408,33	60,00	27,00
061A (40/1)	1,32	0,87	79,21	404,77	60,00	23,00
061B (40/3)	1,21	1,43	77,92	402,52	60,00	22,00
061C (40/6)	1,25	1,99	70,65	399,56	60,00	21,00
¹ Temperature (°C)/time (months); ² Disintegration test according to USP current edition.						

Table 51

Shelf life of Batch 062 400 mg SAME sulphate p-toluenesulfonate per gram granulates (quail/quantitative composition of Example 24)						
Batch (T/t) ¹	Humidity % (K.F.)	Total impurities	S,S	Count mg/gr	Resistance to gastric juice at pH 1,22 (minutes)	Disintegration time at pH 6,82 (minutes)
062(20/0)	1,43	0,64	82,36	408,98	60,00	20,00
062A (25/3)	1,33	0,32	80,53	407,67	60,00	23,00
062B (25/6)	1,36	0,56	77,53	406,42	60,00	22,00

EP 2 598 122 B1

(continued)

Shelf life of Batch 062 400 mg SAME sulphate p-toluenesulfonate per gram granulates (quali/quantitative composition of Example 24)						
Batch (T/t) ¹	Humidity % (K.F.)	Total impurities	S,S	Count mg/gr	Resistance to gastric juice at pH 1,22 (minutes)	Disintegration time at pH 6,82 (minutes)
062C (25/12)	1,23	0,65	74,20	405,62	60,00	24,00
1 Temperature (°C)/time (months); 2 Disintegration test according to USP current edition.						

[0174] The data in Tables 50 and 51 show that both the samples subjected to stress testing and those conserved at room temperature, in the presence of sodium starch glycolate in the coating film, have disintegration times at pH 6.8 within specifications according to the disintegration test described in USP current edition and the variation of the disintegration again at pH 6.8 is constant over time.

EXAMPLE 25: 400 mg IONE SAME/gram gastroresistant granulates

[0175]

A. SAME sulphate p-toluenesulfonate	830,00 mg
B. Sorbitol	43,50 mg
C. Silica (Aerosil®)	2,00 mg
D. Anhydrous microcrystalline cellulose 112	71,00 mg
E. Vegetable magnesium stearate	12,00 mg
Total granule weight	957,00 mg
F. Arginine Shellac®	21,00 mg
G. Titanium dioxide	2,62 mg
H. Talc	7,87 mg
I. Triethyl citrate	7,87 mg
L. Silica (Aerosil®)	2,14 mg
Total granule weight	1000,00 mg

Table 52

Stress test of Batches 063 and 064 - 400 mg SAME sulphate p-toluenesulfonate per gram granulates (quali/quantitative composition of Example 25)						
Batch (T/t) ¹	Humidity% (K.F.)	Total impurities	S,S %	Count mg/gr	Resistance to gastric juice at pH 1,2 ² (minutes)	Disintegration time at pH 6,8 ² (minutes)
063 (20/0)	1,23	0,59	82,45	407,56	60,00	29,00
063A (40/1)	121	0,89	79,00	406,51	60,00	39,00
063B (40/3)	1,32	0,99	74,33	404,89	60,00	50,00
063C (40/6)	1,22	1,69	70,31	403,85	60,00	61,00
064 (20/0)	1,33	0,55	83,45	406,99	60,00	39,00

EP 2 598 122 B1

(continued)

Stress test of Batches 063 and 064 - 400 mg SAME sulphate p-toluenesulfonate per gram granulates (quali/quantitative composition of Example 25)						
Batch (T/t) ¹	Humidity% (K.F.)	Total impurities	S,S %	Count mg/gr	Resistance to gastric juice at pH 1,2 ² (minutes)	Disintegration time at pH 6,8 ² (minutes)
064A (40/1)	1,17	0,32	79,56	406,19	60,00	48,00
064B (40/3)	1,29	1,32	76,32	405,00	60,00	59,00
064C (40/6)	1,17	2,78	72,40	403,53	60,00	62,00
¹ Temperature (°C)/time (months); ² Disintegration test according to USP current edition.						

Table 53

Shelf life of Batch 065 400 mg SAME sulphate p-toluenesulfonate per gram granulate (quali/quantitative composition of Example 25)						
Batch (T/t) ¹	Humidity % (K.F.)	Total impurities	S,S %	Count mg/gr	Resistance to gastric juice at pH 1,2 ² (minutes)	Disintegration time at pH 6,8 ² (minutes)
065(20/0)	1,22	0,53	82,34	408,45	60,00	41,00
065A (25/3)	1,22	0,68	80,54	406,89	60,00	51,00
065B (25/6)	1,34	0,89	78,45	405,72	60,00	60,00
065C (25/12)	1,56	0,98	76,87	403,58	60,00	71,00
¹ Temperature (°C)/time (months); ² Disintegration test according to USP current edition.						

[0176] The data in Tables 52 and 53 show that both the samples subjected to stress testing and those conserved at room temperature, in the absence of sodium starch glycolate in the coating films, have disintegration times at pH 6.8 outside specifications according to the disintegration test described in USP current edition and the variation of the disintegration again at pH 6.8 is not constant over time.

Claims

- Composition comprising shellac and/or a salt thereof and sodium starch glycolate and at least one physiologically acceptable excipient, **characterised in that** it is a coating composition.
- Composition according to claim 1, **characterised in that** said shellac and/or a salt thereof is aqueous or alcoholic, preferably aqueous.
- Composition according to claim 2, **characterised in that** said shellac salt is a potassium salt, an ammonium salt, a basic amino acid salt and/or a mixture thereof, preferably said basic amino acid is selected from among arginine, lysine, ornithine and/or a mixture thereof, more preferably is arginine.
- Composition according to claim 1, **characterised in that** the sodium starch glycolate is sodium starch glycolate of type A or type B and/or a mixture thereof.
- Composition according to claim 1, **characterised in that** sodium starch glycolate is in form of powder with a granulometry comprised between 0.5 and 200 micron, preferably between 10 and 50 micron.

6. Composition according to claim 1, **characterised in that** shellac and/or a salt thereof is contained in an amount between 1 and 99% by weight with respect to the total weight, preferably between 50 and 95% by weight with respect to the total weight.
- 5 7. Composition according to claim 1, **characterised in that** sodium starch glycolate is contained in an amount between 0.05 and 70% by weight with respect to the total weight, preferably between 0.1% and 50% by weight with respect to the total weight.
- 10 8. Composition according to claim 1, **characterised in that** it is in the form of a solution and/or suspension and/or powder to be reconstituted in water, preferably in the form of an aqueous suspension.
9. Composition according to claim 1, **characterised in that** said at least one physiologically acceptable excipient is selected from among plasticizers, suspension agents or glidants and/or dilutants.
- 15 10. Composition according to claim 9, **characterised in that** said plasticizers are selected from among triethyl citrate, polyethylene glycol, polypropylene glycol, glycerol monostearate, polyols, glycerine, vegetable oils and/or a mixture thereof.
- 20 11. Composition according to claim 10, **characterised in that** said plasticizers are contained in an amount between 2 and 50% by weight with respect to the total weight.
12. Composition according to claim 9, **characterised in that** said suspension agents or glidants are selected from among precipitated silica, talc and/or a mixture thereof.
- 25 13. Composition according to claim 9, **characterised in that** said dilutants are selected from among talc, titanium dioxide and/or a mixture thereof.
14. Composition according to any one of the preceding claims, **characterised in that** it is a gastroresistant coating composition.
- 30 15. Composition according to claim 14, **characterised in that** it is a coating composition for solid oral formulations, preferably tablets, capsules, pellets, granules and/or microgranules.
- 35 16. Process for preparing the coating composition according to any one of the preceding claims, comprising the steps of:
 - a) preparing the solution of shellac and/or of a salt thereof, solution A;
 - b) preparing the aqueous suspension of sodium starch glycolate, suspension B;
 - c) mixing solution A and suspension B.
- 40 17. Process according to claim 16, **characterised in that** in step a) said shellac and/or a salt thereof is dissolved in a polar solvent, preferably a C₁-C₄ alcohol, water, and/or in a mixture thereof, more preferably water.
18. Process according to claim 16, **characterised in that** it is carried out at a temperature comprised between 50 and 100°C, preferably between 50 and 80°C.
- 45 19. Solid oral formulation coated with the composition according to any one of claims 1 to 15.
20. Coated solid oral formulation according to claim 19, containing at least one active ingredient and/or nutraceutical, dietetic or food supplement and at least one physiologically acceptable adjuvant.
- 50 21. Coated solid oral formulation according to claim 20, **characterised in that** said at least one active ingredient and/or nutraceutical, dietetic or food supplement is selected from among SAME (S-adenosyl methionine) and/or physiologically acceptable salts thereof, lansoprazole, pantoprazole, ibuprofen, lactic ferments, NADH, SOD, nattokinase, preferably SAME and/or physiologically acceptable salts thereof.
- 55 22. Coated solid oral formulation according to claim 20, in the form of tablets, capsules, pellets, granules and/or microgranules.

23. Coated solid oral formulation according to claims 20 to 22, **characterised in that** it is gastroresistant.

Patentansprüche

- 5 1. Zusammensetzung, welche Schellack und/oder ein Salz davon und Natrium-Stärkeglycolat und mindestens einen physiologisch annehmbaren Exzipienten umfasst, **dadurch gekennzeichnet, dass** sie eine Beschichtungszusammensetzung ist.
- 10 2. Zusammensetzung nach Anspruch 1, **dadurch gekennzeichnet, dass** der Schellack und/oder ein Salz davon wässrig oder alkoholisch, vorzugsweise wässrig ist.
- 15 3. Zusammensetzung nach Anspruch 2, **dadurch gekennzeichnet, dass** das Schellacksalz ein Kaliumsalz, ein Ammoniumsalz, ein basisches Aminosäuresalz und/oder ein Gemisch davon ist, vorzugsweise worin die basische Aminosäure ausgewählt ist unter Arginin, Lysin, Ornithin, und/oder einem Gemisch davon, vorzugsweise Arginin ist.
- 20 4. Zusammensetzung nach Anspruch 1, **dadurch gekennzeichnet, dass** das Natrium-Stärkeglycolat Natrium-Stärkeglycolat Typ A oder Typ B oder ein Gemisch davon ist.
- 25 5. Zusammensetzung nach Anspruch 1, **dadurch gekennzeichnet, dass** das Natrium-Stärkeglycolat in Form eines Pulvers mit einer Granulometrie im Bereich von zwischen 0,5 und 200 Mikron, vorzugsweise zwischen 10 und 50 Mikron ist.
- 30 6. Zusammensetzung nach Anspruch 1, **dadurch gekennzeichnet, dass** der Schellack oder das Salz davon in einer Menge zwischen 1 und 99 Gew.-%, bezogen auf das Gesamtgewicht, vorhanden ist, vorzugsweise zwischen 50 und 95 Gew.-%, bezogen auf das Gesamtgewicht.
- 35 7. Zusammensetzung nach Anspruch 1, **dadurch gekennzeichnet, dass** das Natrium-Stärkeglycolat in einer Menge zwischen 0,05 und 70 Gew.-%, bezogen auf das Gesamtgewicht vorhanden ist, vorzugsweise zwischen 0,1 und 50 Gew.-%, bezogen auf das Gesamtgewicht.
- 40 8. Zusammensetzung nach Anspruch 1, **dadurch gekennzeichnet, dass** sie in Form einer Lösung und/oder Suspension und/oder einem in Wasser wiederherzustellenden Pulver vorliegt, vorzugsweise in Form einer wässrigen Suspension.
- 45 9. Zusammensetzung nach Anspruch 1, **dadurch gekennzeichnet, dass** der mindestens eine physiologisch annehmbare Exzipient ausgewählt ist unter Weichmachern, Suspendierungsmitteln oder Gleitmitteln und/oder Verdünnungsmitteln.
- 50 10. Zusammensetzung nach Anspruch 9, **dadurch gekennzeichnet, dass** die Weichmacher ausgewählt sind unter Triethylcitrat, Polyethylenglycol, Polypropylenglycol, Glycerinmonostearat, Polyolen, Glycerin, Gemüseölen und/oder einem Gemisch davon.
- 55 11. Zusammensetzung nach Anspruch 10, **dadurch gekennzeichnet, dass** die Weichmacher in einer Menge von zwischen 2 und 50 Gew.-%, bezogen auf das Gesamtgewicht, vorhanden sind.
12. Zusammensetzung nach Anspruch 9, **dadurch gekennzeichnet, dass** die Suspendierungsmittel oder Gleitmittel ausgewählt sind unter ausgefälltem Siliziumdioxid, Talk und/oder einem Gemisch davon.
13. Zusammensetzung nach Anspruch 9, **dadurch gekennzeichnet, dass** die Verdünnungsmittel ausgewählt sind unter Talk, Titandioxid und/oder einem Gemisch davon.
14. Zusammensetzung nach einem der vorstehenden Ansprüche, **dadurch gekennzeichnet, dass** sie eine magensaftresistente Zusammensetzung ist.
15. Zusammensetzung nach Anspruch 14, **dadurch gekennzeichnet, dass** sie eine Beschichtungszusammensetzung für feste orale Formulierungen ist, vorzugsweise Tabletten, Kapseln, Kügelchen, Granulate und/oder Mikrogranulate.

16. Verfahren zur Herstellung der Beschichtungszusammensetzung nach einem der vorstehenden Ansprüche, welches die Schritte umfasst:

- a) Herstellen der Lösung von Schellack und/oder einem Salz davon, Lösung A;
- b) Herstellen der wässrigen Suspension von Natrium-Stärkeglycolat, Suspension B;
- c) Mischen der Lösung A und Suspension B.

17. Verfahren nach Anspruch 16, **dadurch gekennzeichnet, dass** in Schritt a) der Schellack und/oder ein Salz davon in einem polaren Lösungsmittel gelöst wird, vorzugsweise in einem C₁-C₄-Alkohol, Wasser und/oder in einem Gemisch davon, mehr bevorzugt Wasser.

18. Verfahren nach Anspruch 16, **dadurch gekennzeichnet, dass** es bei einer Temperatur im Bereich zwischen 50° und 100 °C, vorzugsweise zwischen 50 ° und 80 °C durchgeführt wird.

19. Feste orale Formulierung, welche mit der Zusammensetzung nach einem der Ansprüche 1 bis 15 beschichtet ist.

20. Beschichtete, feste orale Formulierung nach Anspruch 19, welche mindestens einen aktiven Inhaltsstoff und/oder funktionellen, diätetischen oder Nahrungsergänzungs-Stoff beinhaltet und mindestens ein physiologisch annehmbares Adjuvans.

21. Beschichtete feste orale Formulierung nach Anspruch 20, **dadurch gekennzeichnet, dass** der mindestens eine Inhaltsstoff und/oder der funktionelle, diätetische oder Nahrungsergänzungs-Stoff ausgewählt ist unter SAMe (S-Adenosyl-Methionin) und/oder physiologisch annehmbaren Salzen davon, Lansoprazol, Pantoprazol, Ibuprofen, fermentierten Milchprodukten, NADH, SOD, Nattokinase, vorzugsweise SAMe und/oder physiologisch annehmbaren Salzen davon.

22. Beschichtete feste orale Formulierung nach Anspruch 20, in Form von Tabletten, Kapseln, Kügelchen, Granulaten und/oder Mikrogranulaten.

23. Beschichtete feste orale Formulierung nach einem der Ansprüche 20 bis 22, **dadurch gekennzeichnet, dass** sie magensaftresistent ist.

Revendications

1. Composition comprenant de la gomme laque et/ou un sel correspondant et du glycolate d'amidon sodique et au moins un excipient physiologiquement acceptable, **caractérisée en ce qu'il s'agit d'une composition d'enrobage.**

2. Composition selon la revendication 1, **caractérisée en ce que** ladite gomme laque et/ou un sel correspondant est aqueuse (aqueux) ou alcoolique, de préférence aqueuse (aqueux).

3. Composition selon la revendication 2, **caractérisée en ce que** ledit sel de gomme laque est un sel de potassium, un sel d'ammonium, un sel d'acide aminé basique et/ou un mélange de ceux-ci, ledit acide aminé basique étant de préférence choisi parmi l'arginine, la lysine, l'ornithine et/ou un mélange de celles-ci, étant plus préférablement de l'arginine.

4. Composition selon la revendication 1, **caractérisée en ce que** le glycolate d'amidon sodique est du glycolate d'amidon sodique de type A ou de type B et/ou un mélange de ceux-ci.

5. Composition selon la revendication 1, **caractérisée en ce que** le glycolate d'amidon sodique se présente sous la forme d'une poudre ayant une granulométrie comprise entre 0,5 et 200 microns, de préférence entre 10 et 50 microns.

6. Composition selon la revendication 1, **caractérisée en ce que** la gomme laque et/ou un sel correspondant est contenu(e) en une quantité située entre 1 et 99 % en poids par rapport au poids total, de préférence entre 50 et 95 % en poids par rapport au poids total.

7. Composition selon la revendication 1, **caractérisée en ce que** le glycolate d'amidon sodique est contenu en une quantité située entre 0,05 et 70 % en poids par rapport au poids total, de préférence entre 0,1 % et 50 % en poids

par rapport au poids total.

- 5 8. Composition selon la revendication 1, **caractérisée en ce qu'elle** se présente sous la forme d'une solution et/ou d'une suspension et/ou d'une poudre à reconstituer dans l'eau, de préférence sous la forme d'une suspension aqueuse.
9. Composition selon la revendication 1, **caractérisée en ce que** ledit au moins un excipient physiologiquement acceptable est choisi parmi les plastifiants, les agents de suspension ou les glissants et/ou diluants.
- 10 10. Composition selon la revendication 9, **caractérisée en ce que** lesdits plastifiants sont choisis parmi le citrate de triéthyle, le polyéthylène glycol, le polypropylène glycol, le monostéarate de glycérol, les polyols, la glycérine, les huiles végétales et/ou un mélange de ceux-ci.
- 15 11. Composition selon la revendication 10, **caractérisée en ce que** lesdits plastifiants sont contenus en une quantité située entre 2 et 50 % en poids par rapport au poids total.
12. Composition selon la revendication 9, **caractérisée en ce que** lesdits agents de suspension ou glissants sont choisis parmi la silice précipitée, le talc et/ou un mélange de ceux-ci.
- 20 13. Composition selon la revendication 9, **caractérisée en ce que** lesdits diluants sont choisis parmi le talc, le dioxyde de titane et/ou un mélange de ceux-ci.
- 25 14. Composition selon l'une quelconque des revendications précédentes, **caractérisée en ce qu'il** s'agit d'une composition d'enrobage gastrorésistante.
- 30 15. Composition selon la revendication 14, **caractérisée en ce qu'il** s'agit d'une composition d'enrobage pour formulations orales solides, de préférence de comprimés, de capsules, de pellets, de granulés et/ou de microgranulés.
- 35 16. Procédé de préparation de la composition d'enrobage selon l'une quelconque des revendications précédentes, comprenant les étapes consistant à :
 - a) préparer la solution de gomme laque et/ou d'un sel correspondant, solution A ;
 - b) préparer la suspension aqueuse de glycolate d'amidon sodique, suspension B ;
 - c) mélanger la solution A et la suspension B.
- 40 17. Procédé selon la revendication 16, **caractérisé en ce que** dans l'étape a) ladite gomme laque et/ou un sel correspondant est dissoute (dissous) dans un solvant polaire, de préférence un alcool en C₁ à C₄, de l'eau, et/ou dans un mélange de ceux-ci, plus préférablement de l'eau.
- 45 18. Procédé selon la revendication 16, **caractérisé en ce qu'il** est réalisé à une température comprise entre 50 et 100 °C, de préférence entre 50 et 80 °C.
19. Formulation orale solide revêtue de la composition selon l'une quelconque des revendications 1 à 15.
- 50 20. Formulation orale solide enrobée selon la revendication 19, contenant au moins une substance active et/ou un nutraceutique, un complément diététique ou alimentaire et au moins un adjuvant physiologiquement acceptable.
- 55 21. Formulation orale solide enrobée selon la revendication 20, **caractérisée en ce que** ladite (ledit) au moins une substance active et/ou nutraceutique, complément diététique ou alimentaire est choisi(e) parmi la SAME (S-adénosyl méthionine) et/ou les sels physiologiquement acceptables de celle-ci, le lansoprazole, le pantoprazole, l'ibuprofène, les ferments lactiques, le NADH, la SOD, la nattokinase, de préférence la SAME et/ou les sels physiologiquement acceptables de celle-ci.
22. Formulation orale solide enrobée selon la revendication 20, sous la forme de comprimés, de capsules, de pellets, de granulés et/ou de microgranulés.
23. Formulation orale solide enrobée selon les revendications 20 à 22, **caractérisée en ce qu'elle** est gastrorésistante.

REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description

- US 20070071821 A [0023]
- WO 2009064429 A [0024]
- US 20040103821 A [0024]

Sellakot és/vagy annak sóját és nátrium-keményítő-glikolátot tartalmazó kompozíció

SZABADALMI IGÉNYPONTOK

1. Sellakot és/vagy annak sóját és nátrium-keményítő-glikolátot és legalább egy gyógyászatiilag elfogadható excipienst tartalmazó készítmény, azzal jellemezve, hogy bevonó készítmény.

2. Az 1. igénypont szerinti készítmény, azzal jellemezve, hogy az említett sellak és/vagy annak sója vízes vagy alkoholos, előnyösen vízes.

3. A 2. igénypont szerinti készítmény, azzal jellemezve, hogy az említett sellak só nátriumsó, ammóniumsó, bázikus aminosav sója és/vagy ezek keveréke, előnyösen az említett bázikus aminosav az arginin, lizin, ornitin és/vagy keverékeik közül van kiválasztva, előnyösebben arginin.

4. Az 1. igénypont szerinti kompozíció, azzal jellemezve, hogy a nátrium-keményítő-glikolát A vagy B típusú nátrium-keményítő-glikolát és/vagy ezek keveréke.

5. Az 1. igénypont szerinti kompozíció, azzal jellemezve, hogy nátrium-keményítő-glikolát 0,5 és 200 mikron közötti, előnyösen 10 és 50 mikron közötti granulometriájú por formában van.

6. Az 1. igénypont szerinti kompozíció, azzal jellemezve, hogy a sellakot és/vagy annak sóját a teljes tömegre vonatkoztatva 1 és 99 tömeg% közötti mennyiségben, előnyösen 50 és 95 tömeg% közötti mennyiségben tartalmazza.

7. Az 1. igénypont szerinti kompozíció, azzal jellemezve, hogy a nátrium-keményítő-glikolátot a teljes tömegre vonatkoztatva 0,05 tömeg% és 70 tömeg% közötti mennyiségben, előnyösen 0,1 tömeg% és 50 tömeg% mennyiségben tartalmazza.

8. Az 1. igénypont szerinti kompozíció, azzal jellemezve, hogy oldat és/vagy szuszpenzió és/vagy újraképezhető por formában, előnyösen vízes szuszpenzió formában van.

9. Az 1. igénypont szerinti készítmény, azzal jellemezve, hogy az említett legalább egy gyógyászatiilag elfogadható excipiens a lágyítók, szuszpendáló szerek, vagy glidánsok és/vagy hígítószerkeik közül vannak kiválasztva.

10. Az 1. igénypont szerinti készítmény, azzal jellemezve, hogy az említett lágyítók a trietil-citrát, polietilén-glikol, polipropilén-glikol, gliceril-monosztearát, poliolok, glicerín, növényi olajok és/vagy ezek keverékeik közül van kiválasztva.

11. A 10. igénypont szerinti készítmény, azzal jellemezve, hogy az említett lágyítókat 2 és 50 tömeg% közötti mennyiségben tartalmazza a teljes tömegre vonatkoztatva.

12. A 9. igénypont szerinti készítmény, azzal jellemezve, hogy a szuszpendáló szerek vagy glidánsok a kicsapott szilícium-dioxid, talkum és/vagy ezek keverékei közül vannak kiválasztva.

13. A 9. igénypont szerinti készítmény, azzal jellemezve, hogy az említett hígítószerek a talkum, titán-dioxid és/vagy ezek keverékei közül vannak kiválasztva.

14. Az előző igénypontok bármelyike szerinti kompozíció, azzal jellemezve, hogy gasztro-rezisztens bevonó készítmény.

15. A 14. igénypont szerinti készítmény, azzal jellemezve, hogy bevonó készítmény szilárd orális készítményekhez, előnyösen tablettákhoz, kapszulákhoz, pelletekhez, granulátumokhoz és/vagy mikrogranulátumokhoz.

16. Eljárás az előző igénypontok bármelyike szerinti bevonó készítmény előállítására, mely eljárás a következő lépéseket tartalmazza:

- a) sellakból és vagy sójából oldatot készítünk, melyet az A oldatnak nevezünk;
- b) nátrium-keményítő-glikolátból vizes szuszpenziót készítünk, ez a B szuszpenzió,
- c) az A oldatot és a B szuszpenziót összekeverjük.

17. A 16. igénypont szerinti eljárás, azzal jellemezve, hogy a sellak és/vagy sója a) lépés szerinti említett oldását poláros oldószerben, előnyösen 1-4 szénatomos alkoholban, vízben, és/vagy ezek keverékében, előnyösebben vízben végezzük.

18. A 16. igénypont szerinti eljárás, azzal jellemezve, hogy 50 és 100°C közötti hőmérsékleten, előnyösen 50 és 80°C közötti hőmérsékleten végezzük.

19. Az 1-15. igénypontok bármelyike szerinti kompozícióval bevont szilárd orális készítmény.

20. A 19. igénypont szerinti szilárd orális készítmény, mely legalább egy hatóanyagot és/vagy gyógytápanyagot, diétás vagy táplálék kiegészítő anyagot és legalább egy fiziológiailag elfogadható adjuvánst tartalmaz.

21. A 20. igénypont szerinti bevont orális készítmény, azzal jellemezve, hogy az említett legalább egy hatóanyag és/vagy gyógytápanyag, diétás vagy táplálék kiegészítő anyag, a SAME (S-adenozil-metionin) és/vagy annak gyógyászatilag elfogadható sója, lansoprazol, pantoprazol, ibuprofen, tejsavas fermentumok, NADH, SOD, nattokináz közül van kiválasztva, előnyösen SAME és/vagy annak gyógyászatilag elfogadható sója.

22. A 20. igénypont szerinti bevont szilárd orális készítmény, azzal jellemezve, hogy tablettá, kapszula, pellet, granulátum és/vagy mikrogranulátum formában van.

23. A 20-22. igénypontok bármelyike szerinti bevont szilárd orális készítmény, azzal jellemezve, hogy gasztro-rezisztens.

A meghatalmazott


Szabadalmi ügyvivő
SOGK Szabadalmi Ügyvivői Iroda
H-1067 Budapest, Andrássy út 113.
Telefon: 461-1000 Fax: 461-1099
Email: dorzi@sogk.hu